

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 29, 2024

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 000-06217



INTEL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

94-1672743

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

2200 Mission College Boulevard

Santa Clara

California

(Address of principal executive offices)

95054-1549

(Zip Code)

(408) 765-8080

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, \$0.001 par value

INTC

Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of July 26, 2024, the registrant had outstanding 4,276 million shares of common stock.

Table of Contents

Organization of Our Form 10-Q

The order and presentation of content in our Form 10-Q differs from the traditional SEC Form 10-Q format. Our format is designed to improve readability and better present how we organize and manage our business. See "Form 10-Q Cross-Reference Index" within Risk Factors and Other Key Information for a cross-reference index to the traditional SEC Form 10-Q format.

We have defined certain terms and abbreviations used throughout our Form 10-Q in "Key Terms" within the Consolidated Condensed Financial Statements and Supplemental Details.

The preparation of our Consolidated Condensed Financial Statements is in conformity with US GAAP. Our Form 10-Q includes key metrics that we use to measure our business, some of which are non-GAAP measures. See "Non-GAAP Financial Measures" within MD&A for an explanation of these measures and why management uses them and believes they provide investors with useful supplemental information.

	Page
Forward-Looking Statements	1
Availability of Company Information	2
A Quarter in Review	3
Consolidated Condensed Financial Statements and Supplemental Details	
Consolidated Condensed Statements of Income	4
Consolidated Condensed Statements of Comprehensive Income	5
Consolidated Condensed Balance Sheets	6
Consolidated Condensed Statements of Cash Flows	7
Consolidated Condensed Statements of Stockholders' Equity	8
Notes to Consolidated Condensed Financial Statements	9
Key Terms	24
Management's Discussion and Analysis (MD&A)	
Segment Trends and Results	25
Consolidated Condensed Results of Operations	34
Liquidity and Capital Resources	39
Non-GAAP Financial Measures	41
Risk Factors and Other Key Information	
Risk Factors	43
Form 8-K Disclosable Events	43
Quantitative and Qualitative Disclosures About Market Risk	43
Controls and Procedures	43
Issuer Purchases of Equity Securities	44
Rule 10b5-1 Trading Arrangements	44
Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934	44
Exhibits	45
Form 10-Q Cross-Reference Index	46

Forward-Looking Statements

This Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Words such as "accelerate", "achieve", "aim", "ambitions", "anticipate", "believe", "committed", "continue", "could", "designed", "estimate", "expect", "forecast", "future", "goals", "grow", "guidance", "intend", "likely", "may", "might", "milestones", "next generation", "objective", "on track", "opportunity", "outlook", "pending", "plan", "position", "possible", "potential", "predict", "progress", "ramp", "roadmap", "seek", "should", "strive", "targets", "to be", "upcoming", "will", "would", and variations of such words and similar expressions are intended to identify such forward-looking statements, which may include statements regarding:

- our business plans and strategy and anticipated benefits therefrom, including with respect to our IDM 2.0 strategy, Smart Capital strategy, partnerships with Apollo and Brookfield, internal foundry model, updated reporting structure, and AI strategy;
- projections of our future financial performance, including future revenue, gross margins, capital expenditures, and cash flows;
- projected costs and yield trends;
- future cash requirements, the availability, uses, sufficiency, and cost of capital resources, and sources of funding, including for future capital and R&D investments and for returns to stockholders, such as stock repurchases and dividends, and credit ratings expectations;
- future products, services, and technologies, and the expected goals, timeline, ramps, progress, availability, production, regulation, and benefits of such products, services, and technologies, including future process nodes and packaging technology, product roadmaps, schedules, future product architectures, expectations regarding process performance, per-watt parity, and metrics, and expectations regarding product and process leadership;
- investment plans and impacts of investment plans, including in the US and abroad;
- internal and external manufacturing plans, including future internal manufacturing volumes, manufacturing expansion plans and the financing therefor, and external foundry usage;
- future production capacity and product supply;
- supply expectations, including regarding constraints, limitations, pricing, and industry shortages;
- plans and goals related to Intel's foundry business, including with respect to anticipated customers, future manufacturing capacity and service, technology, and IP offerings;
- expected timing and impact of acquisitions, divestitures, and other significant transactions, including the sale of our NAND memory business;
- expected completion and impacts of restructuring activities and cost-saving or efficiency initiatives;
- future social and environmental performance goals, measures, strategies, and results;
- our anticipated growth, future market share, and trends in our businesses and operations;
- projected growth and trends in markets relevant to our businesses;
- anticipated trends and impacts related to industry component, substrate, and foundry capacity utilization, shortages, and constraints;
- expectations regarding government incentives;
- future technology trends and developments, such as AI;
- future macro environmental and economic conditions;
- geopolitical tensions and conflicts and their potential impact on our business;
- tax- and accounting-related expectations;
- expectations regarding our relationships with certain sanctioned parties; and
- other characterizations of future events or circumstances.

Such statements involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied, including those associated with:

- the high level of competition and rapid technological change in our industry;
- the significant long-term and inherently risky investments we are making in R&D and manufacturing facilities that may not realize a favorable return;
- the complexities and uncertainties in developing and implementing new semiconductor products and manufacturing process technologies;
- our ability to time and scale our capital investments appropriately and successfully secure favorable alternative financing arrangements and government grants;
- implementing new business strategies and investing in new businesses and technologies;
- changes in demand for our products;
- macroeconomic conditions and geopolitical tensions and conflicts, including geopolitical and trade tensions between the US and China, the impacts of Russia's war on Ukraine, tensions and conflict affecting Israel and the Middle East, and rising tensions between mainland China and Taiwan;
- the evolving market for products with AI capabilities;

- our complex global supply chain, including from disruptions, delays, trade tensions and conflicts, or shortages;
- product defects, errata and other product issues, particularly as we develop next-generation products and implement next-generation manufacturing process technologies;
- potential security vulnerabilities in our products;
- increasing and evolving cybersecurity threats and privacy risks;
- IP risks including related litigation and regulatory proceedings;
- the need to attract, retain, and motivate key talent;
- strategic transactions and investments;
- sales-related risks, including customer concentration and the use of distributors and other third parties;
- our significantly reduced return of capital in recent years;
- our debt obligations and our ability to access sources of capital;
- complex and evolving laws and regulations across many jurisdictions;
- fluctuations in currency exchange rates;
- changes in our effective tax rate;
- catastrophic events;
- environmental, health, safety, and product regulations;
- our initiatives and new legal requirements with respect to corporate responsibility matters; and
- other risks and uncertainties described in this report, our 2023 Form 10-K and our other filings with the SEC.

Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this Form 10-Q and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business.

Unless specifically indicated otherwise, the forward-looking statements in this Form 10-Q do not reflect the potential impact of any divestitures, mergers, acquisitions, or other business combinations that have not been completed as of the date of this filing. In addition, the forward-looking statements in this Form 10-Q are based on management's expectations as of the date of this filing, unless an earlier date is specified, including expectations based on third-party information and projections that management believes to be reputable. We do not undertake, and expressly disclaim any duty, to update such statements, whether as a result of new information, new developments, or otherwise, except to the extent that disclosure may be required by law.

Availability of Company Information


We use our Investor Relations website, www.intc.com, as a routine channel for distribution of important, and often material, information about us, including our quarterly and annual earnings results and presentations, press releases, announcements, information about upcoming webcasts, analyst presentations, and investor days, archives of these events, financial information, corporate governance practices, and corporate responsibility information. We also post our filings on this website the same day they are electronically filed with, or furnished to, the SEC, including our annual and quarterly reports on Forms 10-K and 10-Q and current reports on Form 8-K, our proxy statements, and any amendments to those reports. All such information is available free of charge. Our Investor Relations website allows interested persons to sign up to automatically receive e-mail alerts when we post financial information and issue press releases, and to receive information about upcoming events. We encourage interested persons to follow our Investor Relations website in addition to our filings with the SEC to timely receive information about the company.

Intel, the Intel logo, Intel Core, and Altera are trademarks of Intel Corporation or its subsidiaries in the US and/or other countries.

** Other names and brands may be claimed as the property of others.*

A Quarter in Review

Total revenue of \$12.8 billion was down \$116 million from Q2 2023, as CCG revenue increased 9%, DCAI revenue decreased 3%, and NEX revenue decreased 1%. CCG revenue increased primarily due to higher notebook and desktop volumes as customer inventory levels improved compared to higher levels in Q2 2023. DCAI revenue decreased due to lower server volume from lower demand in a competitive environment, partially offset by higher server ASPs primarily due to a lower mix of hyperscale customer-related revenue and a higher mix of high core count products. NEX revenue was roughly flat. External Intel Foundry revenue decreased due to lower traditional packaging services and equipment sales. Altera® revenue decreased as customers tempered purchases to reduce existing inventories.



Key Developments

- We achieved a critical milestone on Intel 18A with the release to Intel Foundry customers of Intel 18A PDK 1.0.
- We announced the planned implementation of cost-reduction measures, including reductions in headcount, other operating expenditures, capital expenditures, and cost of sales. These initiatives are designed to accelerate profitable growth, enable further operational efficiency and agility, and create capacity for sustained investment in technology and manufacturing leadership.
- Our Board of Directors declared a Q3 2024 dividend of \$0.125 per share on our common stock consistent with prior quarters. We announced our Board of Directors suspended the declaration of dividends on our common stock starting with Q4 2024, recognizing the importance of prioritizing liquidity to support the investments needed to execute our strategy. The Board of Directors reiterated our long-term commitment to a competitive dividend as cash flows improve to sustainably higher levels.
- As part of our SCIP program, we completed a transaction with Apollo Global Management, Inc. (Apollo), under which Apollo led an investment of \$11.0 billion to acquire a 49% equity interest in an entity related to our Fab 34 in Leixlip, Ireland. Fab 34 is our leading-edge high-volume manufacturing (HVM) facility designed for wafers using the Intel 4 and Intel 3 process technologies.

¹ See "Non-GAAP Financial Measures" within MD&A.

Consolidated Condensed Statements of Income

(In Millions, Except Per Share Amounts; Unaudited)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Net revenue	\$ 12,833	\$ 12,949	\$ 25,557	\$ 24,664
Cost of sales	8,286	8,311	15,793	16,018
Gross margin	4,547	4,638	9,764	8,646
Research and development	4,239	4,080	8,621	8,189
Marketing, general, and administrative	1,329	1,374	2,885	2,677
Restructuring and other charges	943	200	1,291	264
Operating expenses	6,511	5,654	12,797	11,130
Operating income (loss)	(1,964)	(1,016)	(3,033)	(2,484)
Gains (losses) on equity investments, net	(120)	(24)	85	145
Interest and other, net	80	224	225	365
Income (loss) before taxes	(2,004)	(816)	(2,723)	(1,974)
Provision for (benefit from) taxes	(350)	(2,289)	(632)	(679)
Net income (loss)	(1,654)	1,473	(2,091)	(1,295)
Less: Net income (loss) attributable to non-controlling interests	(44)	(8)	(100)	(18)
Net income (loss) attributable to Intel	\$ (1,610)	\$ 1,481	\$ (1,991)	\$ (1,277)
Earnings (loss) per share attributable to Intel—basic	\$ (0.38)	\$ 0.35	\$ (0.47)	\$ (0.31)
Earnings (loss) per share attributable to Intel—diluted	\$ (0.38)	\$ 0.35	\$ (0.47)	\$ (0.31)
Weighted average shares of common stock outstanding:				
Basic	4,267	4,182	4,254	4,168
Diluted	4,267	4,196	4,254	4,168

See accompanying notes.

Consolidated Condensed Statements of Comprehensive Income

(In Millions; Unaudited)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Net income (loss)	\$ (1,654)	\$ 1,473	\$ (2,091)	\$ (1,295)
Changes in other comprehensive income (loss), net of tax:				
Net unrealized holding gains (losses) on derivatives	(153)	(131)	(481)	11
Actuarial valuation and other pension benefits (expenses), net	—	2	—	3
Translation adjustments and other	(1)	4	—	4
Other comprehensive income (loss)	(154)	(125)	(481)	18
Total comprehensive income (loss)	(1,808)	1,348	(2,572)	(1,277)
Less: comprehensive income (loss) attributable to non-controlling interests	(44)	(8)	(100)	(18)
Total comprehensive income (loss) attributable to Intel	\$ (1,764)	\$ 1,356	\$ (2,472)	\$ (1,259)

See accompanying notes.



Consolidated Condensed Balance Sheets

(In Millions; Unaudited)	Jun 29, 2024	Dec 30, 2023
Assets		
Current assets:		
Cash and cash equivalents	\$ 11,287	\$ 7,079
Short-term investments	17,986	17,955
Accounts receivable, net	3,131	3,402
Inventories	11,244	11,127
Other current assets	7,181	3,706
Total current assets	50,829	43,269
Property, plant, and equipment, net of accumulated depreciation of \$100,173 (\$98,010 as of December 30, 2023)	103,398	96,647
Equity investments	5,824	5,829
Goodwill	27,442	27,591
Identified intangible assets, net	4,383	4,589
Other long-term assets	14,329	13,647
Total assets	\$ 206,205	\$ 191,572
Liabilities and stockholders' equity		
Current liabilities:		
Short-term debt	\$ 4,695	\$ 2,288
Accounts payable	9,618	8,578
Accrued compensation and benefits	2,651	3,655
Income taxes payable	1,856	1,107
Other accrued liabilities	13,207	12,425
Total current liabilities	32,027	28,053
Debt	48,334	46,978
Other long-term liabilities	5,410	6,576
Contingencies (Note 13)		
Stockholders' equity:		
Common stock and capital in excess of par value, 4,276 issued and outstanding (4,228 issued and outstanding as of December 30, 2023)	49,763	36,649
Accumulated other comprehensive income (loss)	(696)	(215)
Retained earnings	66,162	69,156
Total Intel stockholders' equity	115,229	105,590
Non-controlling interests	5,205	4,375
Total stockholders' equity	120,434	109,965
Total liabilities and stockholders' equity	\$ 206,205	\$ 191,572

See accompanying notes.

Consolidated Condensed Statements of Cash Flows

(In Millions; Unaudited)	Six Months Ended	
	Jun 29, 2024	Jul 1, 2023
	\$	\$
Cash and cash equivalents, beginning of period	7,079	11,144
Cash flows provided by (used for) operating activities:		
Net income (loss)	(2,091)	(1,295)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation	4,403	3,733
Share-based compensation	1,959	1,661
Restructuring and other charges	1,291	255
Amortization of intangibles	717	909
(Gains) losses on equity investments, net	(84)	(146)
Changes in assets and liabilities:		
Accounts receivable	272	1,137
Inventories	(116)	1,240
Accounts payable	184	(1,102)
Accrued compensation and benefits	(1,309)	(1,340)
Income taxes	(2,174)	(2,186)
Other assets and liabilities	(1,983)	(1,843)
Total adjustments	3,160	2,318
Net cash provided by (used for) operating activities	1,069	1,023
Cash flows provided by (used for) investing activities:		
Additions to property, plant, and equipment	(11,652)	(13,301)
Proceeds from capital-related government incentives	699	49
Purchases of short-term investments	(17,634)	(25,696)
Maturities and sales of short-term investments	17,214	26,957
Other investing	(355)	662
Net cash provided by (used for) investing activities	(11,728)	(11,329)
Cash flows provided by (used for) financing activities:		
Issuance of commercial paper, net of issuance costs	5,804	—
Repayment of commercial paper	(2,609)	(3,944)
Payments on finance leases	—	(96)
Partner contributions	11,861	834
Proceeds from sales of subsidiary shares	—	1,573
Issuance of long-term debt, net of issuance costs	2,975	10,968
Repayment of debt	(2,288)	—
Proceeds from sales of common stock through employee equity incentive plans	631	665
Payment of dividends to stockholders	(1,063)	(2,036)
Other financing	(444)	(453)
Net cash provided by (used for) financing activities	14,867	7,511
Net increase (decrease) in cash and cash equivalents	4,208	(2,795)
Cash and cash equivalents, end of period	\$ 11,287	\$ 8,349
Non-cash supplemental disclosures:		
Acquisition of property, plant, and equipment	\$ 5,544	\$ 5,113
Recognition of capital-related government incentives	\$ 1,281	\$ 46
Cash paid during the period for:		
Interest, net of capitalized interest	\$ 488	\$ 161
Income taxes, net of refunds	\$ 1,555	\$ 1,520

See accompanying notes.

Consolidated Condensed Statements of Stockholders' Equity

(In Millions, Except Per Share Amounts; Unaudited)	Common Stock and Capital in Excess of Par Value		Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Non- Controlling Interests	Total
	Shares	Amount				
Three Months Ended						
Balance as of March 30, 2024	4,257	\$ 38,291	\$ (542)	\$ 68,224	\$ 4,783	\$ 110,756
Net income (loss)	—	—	—	(1,610)	(44)	(1,654)
Other comprehensive income (loss)	—	—	(154)	—	—	(154)
Net proceeds from partner contributions	—	11,012	—	—	426	11,438
Employee equity incentive plans and other	26	5	—	—	—	5
Share-based compensation	—	740	—	—	40	780
Restricted stock unit withholdings	(7)	(285)	—	82	—	(203)
Cash dividends declared (\$0.13 per share of common stock)	—	—	—	(534)	—	(534)
Balance as of June 29, 2024	4,276	\$ 49,763	\$ (696)	\$ 66,162	\$ 5,205	\$ 120,434
Balance as of April 1, 2023						
4,171	\$ 32,829	\$ (419)	\$ 65,649	\$ 2,344	\$ 100,403	
Net income (loss)	—	—	—	1,481	(8)	1,473
Other comprehensive income (loss)	—	—	(125)	—	—	(125)
Net proceeds from sales of subsidiary shares and partner contributions	—	866	—	—	1,092	1,958
Employee equity incentive plans and other	22	6	—	—	—	6
Share-based compensation	—	896	—	—	26	922
Restricted stock unit withholdings	(5)	(267)	—	101	—	(166)
Balance as of July 1, 2023	4,188	\$ 34,330	\$ (544)	\$ 67,231	\$ 3,454	\$ 104,471
Six Months Ended						
Balance as of December 30, 2023	4,228	\$ 36,649	\$ (215)	\$ 69,156	\$ 4,375	\$ 109,965
Net income (loss)	—	—	—	(1,991)	(100)	(2,091)
Other comprehensive income (loss)	—	—	(481)	—	—	(481)
Net proceeds from partner contributions	—	11,012	—	—	849	11,861
Employee equity incentive plans and other	58	631	—	—	—	631
Share-based compensation	—	1,878	—	—	81	1,959
Restricted stock unit withholdings	(10)	(407)	—	60	—	(347)
Cash dividends declared (\$0.25 per share of common stock)	—	—	—	(1,063)	—	(1,063)
Balance as of June 29, 2024	4,276	\$ 49,763	\$ (696)	\$ 66,162	\$ 5,205	\$ 120,434
Balance as of December 31, 2022	4,137	\$ 31,580	\$ (562)	\$ 70,405	\$ 1,863	\$ 103,286
Net income (loss)	—	—	—	(1,277)	(18)	(1,295)
Other comprehensive income (loss)	—	—	18	—	—	18
Net proceeds from sales of subsidiary shares and partner contributions	—	866	—	—	1,541	2,407
Employee equity incentive plans and other	58	665	—	—	—	665
Share-based compensation	—	1,593	—	—	68	1,661
Restricted stock unit withholdings	(7)	(374)	—	139	—	(235)
Cash dividends declared (\$0.49 per share of common stock)	—	—	—	(2,036)	—	(2,036)
Balance as of July 1, 2023	4,188	\$ 34,330	\$ (544)	\$ 67,231	\$ 3,454	\$ 104,471

See accompanying notes.

Notes to Consolidated Condensed Financial Statements

Note 1 : Basis of Presentation

We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with US GAAP, consistent in all material respects with those applied in our 2023 Form 10-K.

We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with our 2023 Form 10-K where we include additional information on our critical accounting estimates, policies, and the methods and assumptions used in our estimates.

Note 2 : Operating Segments

We previously announced the implementation of our internal foundry operating model, which took effect in the first quarter of 2024, and creates a foundry relationship between our Intel Products business (collectively CCG, DCAI, and NEX) and our Intel Foundry business. Intel Products consists substantially of design and development of CPUs and related solutions for third party customers. Intel Foundry consists substantially of process engineering, manufacturing, and foundry services groups that provide manufacturing, test, and assembly services to our Intel Products business and to third party customers. Both businesses utilize marketing, sales, and other support functions.

Our internal foundry model is a key component of our strategy and is designed to reshape our operational dynamics and drive greater transparency, accountability, and focus on costs and efficiency. We also previously announced our intent to operate Altera as a standalone business, with segment reporting beginning in the first quarter of 2024. Altera was previously included in our DCAI segment results. As a result of these changes, we modified our segment reporting in the first quarter of 2024 to align to this new operating model. All prior period segment data has been retrospectively adjusted to reflect the way our Chief Operating Decision Maker (CODM) internally receives information and manages and monitors our operating segment performance starting in fiscal year 2024. There are no changes to our consolidated financial statements for any prior periods.

We organize our business as follows:

- Intel Products:
 - Client Computing Group (CCG)
 - Data Center and AI (DCAI)
 - Network and Edge (NEX)
- Intel Foundry
- All other
 - Altera
 - Mobileye
 - Other

CCG, DCAI, and Intel Foundry qualify as reportable operating segments. NEX, Altera, and Mobileye do not qualify as reportable operating segments; however, we have elected to disclose their results. When we enter into federal contracts, they are aligned to the sponsoring operating segment.

The accounting policies for our segment reporting are the same for Intel as a whole. A summary of the basis for which we report our operating segment revenues and operating margin is as follows:

Intel Products: CCG, DCAI, and NEX

- **Segment revenue:** consists of revenues from third party customers. The Intel Products operating segments represent a substantial majority of Intel consolidated revenue and are derived from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which are based on Intel architecture.
- **Segment expenses:** consists of intersegment charges for product manufacturing and related services from Intel Foundry, external foundry and other manufacturing expenses, product development costs, allocated expenses as described below, and direct operating expenses.

Intel Foundry

- **Segment revenue:** consists substantially of intersegment product and services revenue for wafer fabrication and related products and services sold to Intel Products, Altera, and certain other Intel internal businesses. We recognize intersegment revenue when we satisfy performance obligations as evidenced by the transfer of control of Intel Foundry products and services to the Intel Products businesses, which is generally at the completion of wafer sorting and at the completion of assembly and test services. Intersegment sales are recorded at prices that are intended to approximate market pricing. Intel Foundry also includes certain third party foundry and assembly and test revenues from external customers that were \$77 million in the three months ended June 29, 2024 and \$104 million in the first six months of 2024, compared to \$231 million in the three months ended July 1, 2023 and \$349 million in the first six months of 2023.
- **Segment expenses:** consists of direct expenses for technology development, product manufacturing and services provided by Intel Foundry to internal and external customers, allocated expenses as described below, and direct operating expenses. Direct expenses for product manufacturing includes excess capacity charges that were previously allocated primarily to CCG, DCAI, and NEX.

All Other: Altera & Mobileye

- **Segment revenue:** consists of product revenues from third party customers. Altera revenue is derived from programmable semiconductors, primarily FPGAs, CPLDs, acceleration platforms, software, IP, and related products. Mobileye revenue is derived from advanced driver-assistance systems (ADAS) and autonomous driving technologies and solutions.
- **Segment expenses:** Altera expenses consist of intersegment charges for product manufacturing and related services from Intel Foundry, third party manufacturing expenses, allocated expenses as described below, and direct operating expenses. Mobileye expenses consists of third party direct expenses for product manufacturing and related services for the manufacturing of Mobileye products and direct operating expenses.

Our "all other" category also consists of "other", which includes:

- results of operations from non-reportable segments not otherwise presented, and from start-up businesses that support our initiatives; and
- historical results of operations from divested businesses.

We allocate operating expenses from our sales and marketing group to the Intel Products operating segments, and allocate operating expenses from our finance and administration groups to all of our operating segments, except Mobileye.

We estimate that the substantial majority of our consolidated depreciation expense in the first six months of 2024 and in the first six months of 2023 was incurred by Intel Foundry. Intel Foundry depreciation expense is substantially included in overhead cost pools and then combined with other costs, and subsequently absorbed into inventory as each product passes through the manufacturing process and is sold to Intel Products and other customers. As a result, it is impractical to determine the total depreciation expense included as a component of each Intel Products operating segment's operating income (loss).

We do not allocate to our operating segments corporate operating expenses that primarily consist of:

- restructuring and other charges;
- share-based compensation;
- certain impairment charges; and
- certain acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill.

We do not allocate to our operating segments non-operating items such as:

- gains and losses from equity investments;
- interest and other income; and
- income taxes.

The CODM, who is our CEO, allocates resources to and assesses the performance of each operating segment using information about the operating segment's revenue and operating income (loss). Although the CODM uses operating income (loss) to evaluate the segments, operating costs included in one segment may benefit other segments. The measures regularly provided to and used by our CODM under our new operating model continue to evolve; currently, our CODM does not regularly review or receive discrete asset information by segment.

Intersegment eliminations: Intersegment sales and related gross margin on inventory recorded at the end of the period or sold through to third party customers is eliminated for consolidation purposes. The Intel Products operating segments and Intel Foundry are meant to reflect separate fabless semiconductor and foundry companies. Thus certain intersegment activity is captured within the intersegment eliminations upon consolidation and presented at the Intel consolidated level. This activity primarily relates to inventory reserves, which are determined and recorded based on our accounting policies for Intel as a whole, but are only recorded by the Intel Products operating segments upon transfer of inventory from Intel Foundry. If a reserve is identified prior to the related inventory transferring to Intel Products, that reserve is presented as activity within the intersegment eliminations.

Reporting units and goodwill reallocation: As a result of modifying our segment reporting in the first quarter of 2024, we reallocated goodwill among our affected reporting units on a relative fair value basis. We performed a quantitative goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization. We concluded based on our pre-reorganization impairment test that goodwill was not impaired. As a result of our post-reorganization impairment test, we recognized a non-cash goodwill impairment loss of \$222 million in the first quarter of 2024 related to our Intel Foundry reporting unit as the estimated fair value of the new reporting unit was lower than the assigned carrying value, which now includes substantially all of our allocated property, plant, and equipment. The Intel Foundry reporting unit has no remaining goodwill. The fair value substantially exceeded the carrying value for all remaining reporting units tested as part of our post-reorganization impairment test.

Operating segment and consolidated net revenue and operating income (loss) for each period were as follows:

(In Millions)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Operating segment revenue:				
Intel Products:				
Client Computing Group				
Desktop	\$ 2,527	\$ 2,370	\$ 4,988	\$ 4,249
Notebook	4,480	3,896	9,161	7,303
Other	403	514	794	995
	7,410	6,780	14,943	12,547
Data Center and AI				
Network and Edge	3,045	3,155	6,081	6,056
	1,344	1,364	2,708	2,853
Total Intel Products revenue	\$ 11,799	\$ 11,299	\$ 23,732	\$ 21,456
Intel Foundry				
All other	\$ 4,320	\$ 4,172	\$ 8,689	\$ 9,003
Altera	361	848	703	1,664
Mobileye	440	454	679	912
Other	167	117	361	283
	968	1,419	1,743	2,859
Total all other revenue				
Total operating segment revenue	\$ 17,087	\$ 16,890	\$ 34,164	\$ 33,318
Intersegment eliminations	(4,254)	(3,941)	(8,607)	(8,654)
Total net revenue	\$ 12,833	\$ 12,949	\$ 25,557	\$ 24,664
Segment operating income (loss):				
Intel Products:				
Client Computing Group				
Data Center and AI	\$ 2,497	\$ 1,986	\$ 5,142	\$ 3,166
Network and Edge	276	469	758	491
	139	64	323	(5)
Total Intel Products operating income (loss)	\$ 2,912	\$ 2,519	\$ 6,223	\$ 3,652
Intel Foundry				
All Other	\$ (2,830)	\$ (1,869)	\$ (5,304)	\$ (4,229)
Altera	\$ (25)	\$ 346	\$ (64)	\$ 636
Mobileye	72	129	4	252
Other	(82)	(120)	(187)	(186)
	\$ (35)	\$ 355	\$ (247)	\$ 702
Total all other operating income (loss)	\$ 47	\$ 1,005	\$ 672	\$ 125
Total segment operating income (loss)				
Intersegment eliminations	(291)	(413)	203	43
Corporate unallocated expenses	(1,720)	(1,608)	(3,908)	(2,652)
Total operating income (loss)	\$ (1,964)	\$ (1,016)	\$ (3,033)	\$ (2,484)

Corporate Unallocated Expenses

Corporate unallocated expenses represent costs incurred that are not directly attributed to an operating segment. The nature of these expenses may vary, but primarily consist of restructuring and other charges, share-based compensation, certain impairment charges, and certain acquisition-related costs.

(In Millions)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Acquisition-related adjustments	\$ (265)	\$ (350)	\$ (530)	\$ (721)
Share-based compensation	(780)	(922)	(1,959)	(1,661)
Restructuring and other charges	(943)	(200)	(1,291)	(264)
Other	268	(136)	(128)	(6)
Total corporate unallocated expenses	\$ (1,720)	\$ (1,608)	\$ (3,908)	\$ (2,652)

Note 3 : Non-Controlling Interests

(In Millions)	Jun 29, 2024		Dec 30, 2023	
	Non-Controlling Interests	Non-Controlling Ownership %	Non-Controlling Interests	Non-Controlling Ownership %
Ireland SCIP	\$ 6	49 %	\$ —	— %
Arizona SCIP	3,152	49 %	2,359	49 %
Mobileye	1,886	12 %	1,838	12 %
IMS Nanofabrication	161	32 %	178	32 %
Total Non-controlling interests	\$ 5,205		\$ 4,375	

Semiconductor Co-Investment Program

Ireland SCIP: In the second quarter of 2024, we closed a transaction with Apollo Global Management, Inc., involving the sale of 49% of our interest in an Irish limited liability company (Ireland SCIP) for net proceeds of \$11.0 billion, substantially all of which increased our capital in excess of par value. Ireland SCIP is a VIE that we consolidate into our consolidated financial statements because we are the primary beneficiary. Generally, distributions will be received from Ireland SCIP based on both parties' proportional ownership. Ireland SCIP has the rights to operate Fab 34 in Leixlip, Ireland, and has the rights to the related factory output. We have the right to purchase 100% of the related factory output from Ireland SCIP. We will retain sole ownership of Fab 34, will be engaged as the Fab 34 operator in exchange for variable payments from Ireland SCIP based on the related factory output, and will be required to maintain certain performance standards in our capacity as operator. Once Fab 34 construction is complete, we will be required to purchase minimum quantities of the related factory output from Ireland SCIP or we will be subject to pay certain penalties to Ireland SCIP.

As of June 29, 2024, substantially all of the assets of Ireland SCIP consisted of cash and cash equivalents. The remaining assets and liabilities of Ireland SCIP were eliminated in our consolidated financial statements.

Arizona SCIP: We consolidate the results of an Arizona limited liability company (Arizona SCIP), a VIE, into our consolidated financial statements because we are the primary beneficiary. Generally, contributions will be made to, and distributions will be received from Arizona SCIP based on both parties' proportional ownership. We will be the sole operator and main beneficiary of two new chip factories that will be constructed by Arizona SCIP, and we will have the right to purchase 100% of the related factory output. Once production commences, we will be required to operate Arizona SCIP at minimum production levels measured in wafer starts per week and will be required to limit excess inventory held on site or we will be subject to certain penalties.

We have an unrecognized commitment to fund our respective share of the total construction costs of Arizona SCIP of \$29.0 billion.

As of June 29, 2024, substantially all of the assets of Arizona SCIP consisted of property, plant, and equipment. The remaining assets and liabilities of Arizona SCIP were eliminated in our consolidated financial statements. The assets held by Arizona SCIP, which can be used only to settle obligations of the VIE and are not available to us, were \$6.4 billion as of June 29, 2024 (\$4.8 billion as of December 30, 2023).

Mobileye

In 2022, Mobileye completed its IPO and certain other equity financing transactions. During 2023, we converted 38.5 million of our Mobileye Class B shares into Class A shares, representing 5% of Mobileye's outstanding capital stock, and subsequently sold the Class A shares for \$42 per share as part of a secondary offering, receiving net proceeds of \$1.6 billion and increasing our capital in excess of par value by \$663 million, net of tax. We continue to consolidate the results of Mobileye into our consolidated financial statements.

IMS Nanofabrication

In 2023, we closed agreements to sell a combined 32% minority stake in our IMS business, a business within our Intel Foundry operating segment—including a 20% stake to Bain Capital and a 10% stake to Taiwan Semiconductor Manufacturing Company. Net proceeds resulting from the minority stake sales totaled \$1.4 billion, and our capital in excess of par value increased by \$958 million, net of tax. We continue to consolidate the results of IMS into our consolidated financial statements.

Note 4 : Earnings (Loss) Per Share

We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period.

(In Millions, Except Per Share Amounts)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Net income (loss)	\$ (1,654)	\$ 1,473	\$ (2,091)	\$ (1,295)
Less: Net income (loss) attributable to non-controlling interests	(44)	(8)	(100)	(18)
Net income (loss) attributable to Intel	\$ (1,610)	\$ 1,481	\$ (1,991)	\$ (1,277)
Weighted average shares of common stock outstanding—basic	4,267	4,182	4,254	4,168
Dilutive effect of employee equity incentive plans	—	14	—	—
Weighted average shares of common stock outstanding—diluted	4,267	4,196	4,254	4,168
Earnings (loss) per share attributable to Intel—basic	\$ (0.38)	\$ 0.35	\$ (0.47)	\$ (0.31)
Earnings (loss) per share attributable to Intel—diluted	\$ (0.38)	\$ 0.35	\$ (0.47)	\$ (0.31)

Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan.

Due to our net losses in the three and six months ended June 29, 2024 and the six months ended July 1, 2023, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan had an anti-dilutive effect on diluted loss per share for these periods and were excluded from the computation of diluted loss per share. Securities that were anti-dilutive were insignificant in all periods presented.

Note 5 : Other Financial Statement Details

Accounts Receivable

We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as *cash provided by operating activities* in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were \$1.0 billion during the first six months of 2024 (\$1.0 billion in the first six months of 2023). After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution.

Inventories

(In Millions)	Jun 29, 2024		Dec 30, 2023	
Raw materials	\$ 1,284		\$ 1,166	
Work in process	6,294		6,203	
Finished goods	3,666		3,758	
Total inventories	\$ 11,244		\$ 11,127	

Other Accrued Liabilities

Other accrued liabilities include deferred compensation of \$3.0 billion as of June 29, 2024 (\$2.9 billion as of December 30, 2023).

Interest and Other, Net

(In Millions)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Interest income	\$ 320	\$ 313	\$ 643	\$ 647
Interest expense	(294)	(214)	(552)	(407)
Other, net	54	125	134	125
Total interest and other, net	\$ 80	\$ 224	\$ 225	\$ 365

Interest expense is net of \$374 million of interest capitalized in the second quarter of 2024 and \$737 million in the first six months of 2024 (\$381 million in the second quarter of 2023 and \$744 million in the first six months of 2023).

Note 6 : Restructuring and Other Charges

(In Millions)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Employee severance and benefit arrangements	\$ 165	\$ 171	\$ 294	\$ 132
Litigation charges and other	778	20	778	97
Asset impairment charges	—	9	219	35
Total restructuring and other charges	\$ 943	\$ 200	\$ 1,291	\$ 264

Employee severance and benefit arrangements includes charges of \$165 million in the three months ended June 29, 2024 and \$294 million in the six months ended June 29, 2024 relating to actions taken to streamline operations and to reduce costs. We expect these actions to be substantially completed by the fourth quarter of 2024, but this is subject to change. Any changes to the estimates or timing will be reflected in our results of operations.

Litigation charges and other includes a charge of \$780 million in the second quarter of 2024 arising out of the R2 litigation. Refer to "Note 13: Contingencies" within Notes to Consolidated Condensed Financial Statements for further information on legal proceedings.

Asset impairment charges includes a goodwill impairment loss of \$222 million in the first quarter of 2024 related to our Intel Foundry reporting unit. Refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for further information on our business reorganization and goodwill impairment.

Note 7 : Income Taxes

(In Millions)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Income (loss) before taxes	\$ (2,004)	\$ (816)	\$ (2,723)	\$ (1,974)
Provision for (benefit from) taxes	\$ (350)	\$ (2,289)	\$ (632)	\$ (679)
Effective tax rate	17.5 %	280.5 %	23.2 %	34.4 %

In the second quarter of 2024 and YTD 2024, our benefit from income taxes was determined using the actual effective tax rate, adjusted for discrete items. We also utilized the actual effective tax rate method for the YTD 2023 period, and had a catch up adjustment to benefit from taxes during the second quarter of 2023 to conform to this methodology. We use the actual effective tax rate for the year-to-date period, adjusted for discrete items, if any, under certain circumstances where we are unable to make a reliable estimate of the annual effective tax rate. We used this approach in all periods presented due to the variability of the rate as a result of fluctuations in forecasted income and the effects of being taxed in multiple tax jurisdictions.

Note 8 : Investments

Short-term Investments

Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments, and are recorded within *cash and cash equivalents* and *short-term investments* on the Consolidated Condensed Balance Sheets. Government debt includes instruments such as non-US government bills and bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of June 29, 2024 and December 30, 2023, substantially all time deposits were issued by institutions outside the US.

For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in *interest and other, net*. The fair value of our hedged investments was \$17.6 billion as of June 29, 2024 (\$17.1 billion as of December 30, 2023). For hedged investments still held at the reporting date, we recorded net losses of \$139 million in the second quarter of 2024 and net losses of \$366 million in the first six months of 2024 (\$183 million of net losses in the second quarter of 2023 and \$91 million of net losses in the first six months of 2023). We recorded net gains on the related derivatives of \$132 million in the second quarter of 2024 and net gains of \$390 million in the first six months of 2024 (\$237 million of net gains in the second quarter of 2023 and net gains of \$124 million in the first six months of 2023).

Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in *accumulated other comprehensive income (loss)* and realized gains or losses recorded in *interest and other, net*. The adjusted cost of our unhedged investments was \$7.7 billion as of June 29, 2024 (\$4.7 billion as of December 30, 2023), which approximated the fair value for these periods.

The fair value of marketable debt investments, by contractual maturity, as of June 29, 2024, was as follows:

(In Millions)	Fair Value
Due in 1 year or less	\$ 11,498
Due in 1–2 years	1,987
Due in 2–5 years	6,141
Due after 5 years	241
Instruments not due at a single maturity date ¹	5,396
Total	\$ 25,263

¹ Instruments not due at a single maturity date is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents.

Equity Investments

(In Millions)	Jun 29, 2024	Dec 30, 2023
Marketable equity securities ¹	\$ 1,246	\$ 1,194
Non-marketable equity securities	4,574	4,630
Equity method investments	4	5
Total	\$ 5,824	\$ 5,829

¹ Substantially all of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.

The components of gains (losses) on equity investments, net for each period were as follows:

(In Millions)	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Ongoing mark-to-market adjustments on marketable equity securities	\$ (43)	\$ (85)	\$ (134)	\$ 103
Observable price adjustments on non-marketable equity securities	25	—	49	10
Impairment charges	(91)	(38)	(159)	(74)
Sale of equity investments and other ¹	(11)	99	329	106
Total gains (losses) on equity investments, net	\$ (120)	\$ (24)	\$ 85	\$ 145

¹ Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions.

Note 9 : Divestitures

NAND Memory Business

We sold our NAND memory technology and manufacturing business (the NAND OpCo Business) to SK hynix Inc. (SK hynix) which we deconsolidated upon closing the first phase of the transaction on December 29, 2021. We have a receivable within *other current assets* for the transaction's remaining proceeds of \$2.0 billion, which remains outstanding as of June 29, 2024 and will be received upon the second closing of the transaction, expected to be in March 2025.

In connection with the transaction, we have a wafer manufacturing and sale agreement that includes incentives and penalties that are contingent on the cost of operation and output of the NAND OpCo Business. These incentives and penalties present a maximum exposure of up to \$500 million annually, and \$1.5 billion in the aggregate. We are currently in negotiations with SK hynix to update the operating plan of the NAND OpCo Business, which may impact the metrics associated with the incentives and penalties and our expectations of the performance of the NAND OpCo Business against those metrics.

We were reimbursed for costs that we incurred on behalf of the NAND OpCo Business for corporate function services, which include human resources, information technology, finance, supply chain, and other compliance requirements. We recorded a receivable related to these reimbursable costs due from the NAND OpCo Business, a deconsolidated entity, of \$144 million within *other current assets* as of June 29, 2024 (\$145 million recorded as of December 30, 2023).

Note 10 : Borrowings

In the second quarter of 2024, we remarketed \$438 million aggregate principal amount of bonds issued by the Industrial Development Authority of the City of Chandler, Arizona. In accordance with loan agreements we entered into with the Industrial Development Authority of the City of Chandler, Arizona, the bonds are unsecured general obligations. The bonds mature in 2049 and have a 4.00% coupon. The bonds are subject to optional tender starting in February 2029 and mandatory tender in June 2029, at which time we may remarket the bonds for a new term period.

In the first quarter of 2024, we issued a total of \$2.6 billion aggregate principal amount of senior notes comprised of \$500 million in 5.00% senior notes due 2031, \$900 million in 5.15% senior notes due 2034 and \$1.2 billion in 5.60% senior notes due 2054. All of our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our senior fixed rate notes rank equally in the right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries.

In the first quarter of 2024, we expanded both our 5-year \$5.0 billion revolving credit facility agreement and our 364-day \$5.0 billion credit facility agreement, to \$7.0 billion and \$8.0 billion, respectively, and the maturity dates were extended by one year to February 2029 and January 2025, respectively. These credit facilities are unsecured general obligations. The revolving credit facilities had no borrowings outstanding as of June 29, 2024.

We have an ongoing authorization from our Board of Directors to borrow up to \$10.0 billion under our commercial paper program. In the second quarter of 2024, we settled in cash \$2.6 billion of our commercial paper and had \$3.2 billion of 5.48% - 5.55% commercial paper outstanding as of June 29, 2024, which mature in July 2024 (no commercial paper outstanding as of December 30, 2023). Borrowings under the commercial paper program are unsecured general obligations.

Note 11 : Fair Value

Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis

(In Millions)	Jun 29, 2024				Dec 30, 2023			
	Fair Value Measured and Recorded at Reporting Date Using				Fair Value Measured and Recorded at Reporting Date Using			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets								
Cash equivalents:								
Corporate debt	\$ —	\$ 616	\$ —	\$ 616	\$ —	\$ 769	\$ —	\$ 769
Financial institution instruments ¹	5,326	1,333	—	6,659	2,241	835	—	3,076
Government debt ²	2	—	—	2	—	—	—	—
Reverse repurchase agreements	—	2,915	—	2,915	—	2,554	—	2,554
Short-term investments:								
Corporate debt	—	5,781	—	5,781	—	6,951	—	6,951
Financial institution instruments ¹	70	3,319	—	3,389	33	4,215	—	4,248
Government debt ²	8	8,808	—	8,816	—	6,756	—	6,756
Other current assets:								
Derivative assets	131	681	—	812	366	809	—	1,175
Marketable equity securities	1,246	—	—	1,246	1,194	—	—	1,194
Other long-term assets:								
Derivative assets	—	2	—	2	—	21	—	21
Total assets measured and recorded at fair value	\$ 6,783	\$ 23,455	\$ —	\$ 30,238	\$ 3,834	\$ 22,910	\$ —	\$ 26,744
Liabilities								
Other accrued liabilities:								
Derivative liabilities	\$ 4	\$ 477	\$ 123	\$ 604	\$ —	\$ 541	\$ 99	\$ 640
Other long-term liabilities:								
Derivative liabilities	—	580	—	580	—	479	—	479
Total liabilities measured and recorded at fair value	\$ 4	\$ 1,057	\$ 123	\$ 1,184	\$ —	\$ 1,020	\$ 99	\$ 1,119

¹ Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, commercial paper, notes and bonds issued by financial institutions.

² Level 1 investments consist of US Treasury securities. Level 2 investments consist primarily of non-US government debt.

Assets Measured and Recorded at Fair Value on a Non-Recurring Basis

Our non-marketable equity securities, equity method investments, and certain non-financial assets—such as intangible assets, goodwill, and property, plant, and equipment—are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3.

Financial Instruments Not Recorded at Fair Value on a Recurring Basis

Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, certain other receivables, and issued debt. We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of June 29, 2024 was \$546 million (the aggregate carrying value as of December 30, 2023 was \$559 million).

We classify the fair value of issued debt (excluding any commercial paper) as Level 2. The fair value of our issued debt was \$45.9 billion as of June 29, 2024 (\$47.6 billion as of December 30, 2023).

Note 12 : Derivative Financial Instruments

Volume of Derivative Activity

Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows:

(In Millions)	Jun 29, 2024	Dec 30, 2023
Foreign currency contracts	\$ 32,303	\$ 30,064
Interest rate contracts	17,882	18,363
Other	2,539	2,103
Total	\$ 52,724	\$ 50,530

The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was \$12.0 billion as of June 29, 2024 and December 30, 2023.

Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets

(In Millions)	Jun 29, 2024		Dec 30, 2023	
	Assets ¹	Liabilities ²	Assets ¹	Liabilities ²
Derivatives designated as hedging instruments:				
Foreign currency contracts ³	\$ 38	\$ 418	\$ 255	\$ 142
Interest rate contracts	—	699	—	578
Total derivatives designated as hedging instruments	\$ 38	\$ 1,117	\$ 255	\$ 720
Derivatives not designated as hedging instruments:				
Foreign currency contracts ³	\$ 407	\$ 56	\$ 314	\$ 363
Interest rate contracts	238	7	261	36
Equity contracts	131	4	366	—
Total derivatives not designated as hedging instruments	\$ 776	\$ 67	\$ 941	\$ 399
Total derivatives	\$ 814	\$ 1,184	\$ 1,196	\$ 1,119

¹ Derivative assets are recorded as other assets, current and long-term.

² Derivative liabilities are recorded as other liabilities, current and long-term.

³ A substantial majority of these instruments mature within 12 months.

Amounts Offset in the Consolidated Condensed Balance Sheets

Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows:

(In Millions)	Jun 29, 2024					
				Gross Amounts Not Offset in the Balance Sheet		
	Gross Amounts Recognized	Gross Amounts Offset in the Balance Sheet	Net Amounts Presented in the Balance Sheet	Financial Instruments	Cash and Non-Cash Collateral Received or Pledged	Net Amount
Assets:						
Derivative assets subject to master netting arrangements	\$ 706	\$ —	\$ 706	\$ (331)	\$ (375)	\$ —
Reverse repurchase agreements	\$ 2,915	\$ —	\$ 2,915	\$ —	\$ (2,915)	\$ —
Total assets	\$ 3,621	\$ —	\$ 3,621	\$ (331)	\$ (3,290)	\$ —
Liabilities:						
Derivative liabilities subject to master netting arrangements	\$ 1,178	\$ —	\$ 1,178	\$ (331)	\$ (742)	\$ 105
Total liabilities	\$ 1,178	\$ —	\$ 1,178	\$ (331)	\$ (742)	\$ 105
 Dec 30, 2023						
(In Millions)	Gross Amounts Not Offset in the Balance Sheet					
	Gross Amounts Recognized	Gross Amounts Offset in the Balance Sheet	Net Amounts Presented in the Balance Sheet	Financial Instruments	Cash and Non-Cash Collateral Received or Pledged	Net Amount
Assets:						
Derivative assets subject to master netting arrangements	\$ 1,047	\$ —	\$ 1,047	\$ (617)	\$ (430)	\$ —
Reverse repurchase agreements	\$ 2,554	\$ —	\$ 2,554	\$ —	\$ (2,554)	\$ —
Total assets	\$ 3,601	\$ —	\$ 3,601	\$ (617)	\$ (2,984)	\$ —
Liabilities:						
Derivative liabilities subject to master netting arrangements	\$ 1,111	\$ —	\$ 1,111	\$ (617)	\$ (399)	\$ 95
Total liabilities	\$ 1,111	\$ —	\$ 1,111	\$ (617)	\$ (399)	\$ 95

We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate.

Derivatives in Cash Flow Hedging Relationships

The before-tax net gains or losses attributed to cash flow hedges recognized in *other comprehensive income (loss)* were \$227 million net losses in the second quarter of 2024 and \$658 million net losses in the first six months of 2024 (\$245 million net losses in the second quarter of 2023 and \$191 million net losses in the first six months of 2023). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented.

During the first six months of 2024 and 2023, the amounts excluded from effectiveness testing were insignificant.

Derivatives in Fair Value Hedging Relationships

The effects of derivative instruments designated as fair value hedges, recognized in *interest and other, net* for each period were as follows:

(In Millions)	Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income			
	Three Months Ended		Six Months Ended	
	Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
Interest rate contracts	\$ 24	\$ (213)	\$ (120)	\$ (21)
Hedged items	(24)	213	120	21
Total	\$ —	\$ —	\$ —	\$ —

The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows:

Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included (In Millions)	Carrying Amount of the Hedged Item Assets/(Liabilities)		Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities)	
	Jun 29, 2024	Dec 30, 2023	Jun 29, 2024	Dec 30, 2023
	\$ (11,299)	\$ (11,419)	\$ 698	\$ 578
Long-term debt				

Derivatives Not Designated as Hedging Instruments

The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows:

(In Millions)	Location of Gains (Losses) Recognized in Income on Derivatives	Three Months Ended		Six Months Ended	
		Jun 29, 2024	Jul 1, 2023	Jun 29, 2024	Jul 1, 2023
		\$ 190	\$ 211	\$ 536	\$ 212
Foreign currency contracts	Interest and other, net	\$ 34	\$ 124	\$ 151	\$ 90
Interest rate contracts	Interest and other, net	56	100	193	215
Other	Various				
Total		\$ 280	\$ 435	\$ 880	\$ 517

Note 13 : Contingencies

Legal Proceedings

We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. We have accrued a charge of \$1.0 billion related to litigation involving VLSI (see VLSI Technology LLC v. Intel below), a charge of \$780 million related to three separate confidential agreements with R2, Third Point, and TRGP we anticipate entering into (see R2 Semiconductor Patent Litigation below), and a charge of \$401 million related to an EC-imposed fine (see European Commission Competition Matter below). Excluding the VLSI claims and the R2 matter, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Unless specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time.

European Commission Competition Matter

In 2009, the EC found that we had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged "conditional rebates and payments" that required customers to purchase all or most of their x86 microprocessors from us and by making alleged "payments to prevent sales of specific rival products." The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009.

We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. In January 2022, the General Court annulled the EC's 2009 findings against us regarding rebates, as well as the €1.1 billion fine imposed on Intel, which was returned to us in February 2022. The General Court's January 2022 decision did not annul the EC's 2009 finding that we made payments to prevent sales of specific rival products.

In April 2022 the EC appealed the General Court's decision to the Court of Justice, which has indicated it will deliver its judgment in October 2024. In addition, in September 2023 the EC imposed a €376 million (\$401 million) fine against us based on its finding that we made payments to prevent sales of specific rival products. We have appealed the EC's decision. We have accrued a charge for the fine and are unable to make a reasonable estimate of the potential loss or range of losses in excess of this amount given the procedural posture and the nature of these proceedings.

In a related matter, in April 2022 we filed applications with the General Court seeking an order requiring the EC to pay us approximately €593 million in default interest on the original €1.1 billion fine that was held by the EC for 12 years, which applications have been stayed pending the EC's appeal of the General Court's January 2022 decision.

Litigation Related to Security Vulnerabilities

In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, the first variants of which are now commonly referred to as "Spectre" and "Meltdown," that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available.

As of July 31, 2024, consumer class action lawsuits against us were pending in the US and Canada. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by our actions and/or omissions in connection with Spectre, Meltdown, and other variants of this class of security vulnerabilities that have been identified since 2018, and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the US, class action suits filed in various jurisdictions between 2018 and 2021 were consolidated for all pretrial proceedings in the US District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs' failure to plead a viable claim. The Ninth Circuit Court of Appeals affirmed the district court's judgment in November 2023, ending the litigation. In November 2023, new plaintiffs filed a consumer class action complaint in the US District Court for the Northern District of California with respect to a further vulnerability variant disclosed in August 2023 and commonly referred to as "Downfall." We moved to dismiss that complaint in January 2024. In Canada, an initial status conference has not yet been scheduled in one case relating to Spectre and Meltdown pending in the Superior Court of Justice of Ontario, and a stay of a second case pending in the Superior Court of Justice of Quebec is in effect. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. Given the procedural posture and the nature of these cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these matters.

Litigation Related to 7nm Product Delay Announcement

Multiple securities class action lawsuits were filed in the US District Court for the Northern District of California against us and certain officers following our July 2020 announcement of 7nm product delays. The court consolidated the lawsuits and appointed lead plaintiffs in October 2020, and in January 2021 plaintiffs filed a consolidated complaint. Plaintiffs purported to represent all persons who purchased or otherwise acquired our common stock from October 25, 2019 through October 23, 2020, and they generally alleged that defendants violated the federal securities laws by making false or misleading statements about the timeline for 7nm products. The district court granted the defendants' motion to dismiss the consolidated complaint and entered judgment in April 2023. The Ninth Circuit affirmed the district court's judgment in April 2024, and plaintiffs did not appeal the Ninth Circuit's ruling.

Litigation Related to Patent and IP Claims

We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business.

VLSI Technology LLC v. Intel

In October 2017, VLSI Technology LLC (VLSI) filed a complaint against us in the US District Court for the Northern District of California alleging that various Intel FPGA and processor products infringe eight patents VLSI acquired from NXP Semiconductors, N.V. (NXP). VLSI sought damages, attorneys' fees, costs and interest. Intel prevailed on all eight patents and the court entered final judgment in April 2024. In April 2019, VLSI filed three infringement suits against us in the US District Court for the Western District of Texas accusing various of our processors of infringement of eight additional patents it had acquired from NXP:

- The first Texas case went to trial in February 2021, and the jury awarded VLSI \$1.5 billion for literal infringement of one patent and \$675 million for infringement of another patent under the doctrine of equivalents. In April 2022, the court entered final judgment, awarding VLSI \$2.2 billion in damages and approximately \$162 million in pre-judgment and post-judgment interest. We appealed the judgment to the Federal Circuit Court of Appeals, including the court's rejection of Intel's claim to have a license from Fortress Investment Group's acquisition of Finjan. The Federal Circuit Court heard oral argument in October 2023. In December 2023, the Federal Circuit reversed the finding of infringement as to the patent for which VLSI was awarded \$675 million. The Federal Circuit affirmed the finding of infringement as to the patent for which VLSI had been awarded \$1.5 billion, but vacated the damages award and sent the case back to the trial court for further damages proceedings on that patent. The Federal Circuit also ruled that Intel can advance the defense that it is licensed to VLSI's patents. In December 2021 and January 2022 the Patent Trial and Appeal Board (PTAB) instituted Inter Partes Reviews (IPR) on the claims found to have been infringed in the first Texas case, and in May and June 2023 found all of those claims unpatentable; VLSI has appealed the PTAB's decision. In March 2024, Intel filed a motion to stay the case pending appeals of the IPRs. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents.
- The second Texas case went to trial in April 2021, and the jury found that we do not infringe the asserted patents. VLSI had sought approximately \$3.0 billion for alleged infringement, plus enhanced damages for willful infringement. The court has not yet entered final judgment.
- The third Texas case went to trial in November 2022, with VLSI asserting one remaining patent. The jury found the patent valid and infringed, and awarded VLSI approximately \$949 million in damages, plus interest and a running royalty. The court has not yet entered final judgment. In February 2023, we filed motions for a new trial and for judgment as a matter of law notwithstanding the verdict on various grounds. Further appeals are possible. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents, and the court granted Intel's motion that same month.

In May 2019, VLSI filed a case in Shenzhen Intermediate People's Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserted one patent against certain Intel Core processors. Defendants filed an invalidation petition in October 2019 with the China National Intellectual Property Administration (CNIPA) which held a hearing in September 2021. The Shenzhen court held trial proceedings in July 2021, and September 2023. VLSI sought an injunction as well as RMB 1.3 million in costs and expenses, but no damages. In September 2023, the CNIPA invalidated every claim of the asserted patent. In November 2023, the trial court dismissed VLSI's case.

In May 2019, VLSI filed a case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. asserting one patent against certain Intel core processors. The court held a trial hearing in December 2020, where VLSI requested expenses (RMB 300 thousand) and an injunction. In December 2022, we filed a petition to invalidate the patent at issue. The court held a second trial hearing in May 2022, and in October 2023, issued a decision finding no infringement and dismissing all claims. In November 2023, VLSI appealed the finding of non-infringement.

In July 2024, Intel filed suit against VLSI in U.S. District Court for the District of Delaware requesting the court find Intel is licensed to VLSI's patents.

As of June 29, 2024, we have accrued a charge of approximately \$1.0 billion related to the VLSI litigation. While we dispute VLSI's claims and intend to vigorously defend against them, we are unable to make a reasonable estimate of losses in excess of recorded amounts given recent developments and future proceedings.

R2 Semiconductor Patent Litigation

In November 2022, R2 Semiconductor, Inc. (R2) filed a lawsuit in the High Court of Justice in the UK against Intel Corporation (UK) Limited and Intel Corporation, and a lawsuit in the Dusseldorf Regional Court in Germany against Intel Deutschland GmbH and certain Intel customers. R2 asserts one European patent is infringed by Intel's Ice Lake, Tiger Lake, Alder Lake and Ice Lake Server (Xeon) processors (the accused products), and customer servers and laptops that contain those processors. R2 seeks an injunction in both actions prohibiting the sale and requiring the recall of the alleged infringing products. Intel is indemnifying its customers in the German lawsuit.

Intel disputes R2's claims and intends to defend the lawsuits vigorously. In December 2022, Intel responded in the UK action that the asserted patent is not infringed and that the patent is invalid. Trial in the UK matter took place in April 2024. In July 2024, the UK High Court of Justice found the UK part of R2's European patent invalid.

In April 2023, defendants filed statements of defense in the German action that the asserted patent is not infringed and that an injunction would be a disproportionate remedy. In May 2023, defendants also filed a nullity action in the German Federal Patent Court on the ground that the asserted patent is invalid.

In December 2023, the German Federal Patent Court issued a preliminary opinion finding R2's patent valid. A trial in the German Federal Patent Court, followed by a decision on validity is expected in October 2024. In December 2023, the court in Dusseldorf held a trial on the issue of infringement. In February 2024, the court found Intel's processors infringe and issued an injunction and recall order against Intel and its customers. R2 has not yet sought to enforce the order. Intel has appealed the decision. In April 2024, Intel also filed a complaint with the Constitutional Court seeking a stay and a reversal of the finding of infringement and filed additional evidence with the appeals court to demonstrate that it does not infringe R2's patent. In May 2024, the Constitutional Court declined to consider Intel's complaint.

In March 2024, R2 asserted the same patent against Fujitsu and Amazon Web Services in Dusseldorf Regional Court, accusing Ice Lake and Sapphire Rapids in the AWS suit; and Tiger Lake, Ice Lake, Alder Lake, Raptor Lake, and Sapphire Rapids in the Fujitsu suit. R2 seeks an injunction, recall and damages. Intel is indemnifying and defending its customers. In June 2024, defendants filed a writ setting out their defenses.

In March 2024, Intel Corporation Italia S.P.A. filed an action in the Tribunale di Milano seeking an order that Intel processors do not infringe R2's patent. In May 2024, R2 filed suit in Milan against Intel Corporation Italia S.P.A. and Italian affiliates of customers Dell, HP, and HPE, accusing Intel's Ice Lake (server and client), Tiger Lake, Alder Lake, and Raptor Lake processors of infringing its patent, and requesting that its suit be consolidated with Intel Corporation Italia S.P.A.'s suit. R2 is requesting an injunction and damages. In June 2024, R2 responded to the suit filed by Intel Corporation Italia S.P.A. and asserted counterclaims of infringement against the same processors R2 accused in its suit.

In April 2024, R2 filed an action against Intel and its customers Dell, HP, and HPE for patent infringement in before the Tribunal Judiciaire of Paris. Intel and its customers have filed a nullity action against the patent in France.

In light of the potential disruption to Intel's and its customers' businesses in Europe were the Dusseldorf Regional Court's injunction and recall order enforced before a decision by the appeals court is expected, the significant delay expected before a decision by the appeals court, and the additional ongoing and potential litigation across other jurisdictions and with respect to other Intel processors and customers, we are in negotiations to enter into three separate confidential agreements with R2, Third Point (the controlling shareholder) and TRGP Capital (a third-party organization funding the lawsuits) to resolve the injunction enforcement risk and related pending litigation, and provide for broad-based litigation peace with these entities, which may include rights to other technology and services to Intel. Based on the anticipated agreements, we recorded a current period charge of \$780 million, substantially all of which is attributable to the proposed broad-based litigation peace.

Key Terms

We use terms throughout our document that are specific to Intel or that are abbreviations that may not be commonly known or used. Below is a list of these terms used in our document.

Term	Definition
5G	The fifth-generation mobile network, which brings dramatic improvements in network speeds and latency, and which we view as a transformative technology and opportunity for many industries
AI	Artificial intelligence
ASP	Average selling price
Back end services	Includes assembly, test and packaging services
CCG	Client Computing Group operating segment
CODM	Chief operating decision maker
CPU	Processor or central processing unit
CPLD	Complex programmable logic device
DCAI	Data Center and Artificial Intelligence operating segment
EC	European Commission
EPS	Earnings per share
2023 Form 10-K	Annual Report on Form 10-K for the year ended December 30, 2023
Form 10-Q	Quarterly Report on Form 10-Q for the quarter ended June 29, 2024
FPGA	Field-programmable gate array
HPC	High performance computing
IDM 2.0	Evolution of our IDM model that combines our internal factory network, strategic use of foundry capacity and our IFS business to position us to drive technology and product leadership
IP	Intellectual property
IPO	Initial public offering
MD&A	Management's Discussion and Analysis
MG&A	Marketing, general, and administrative
NAND	NAND flash memory
NEX	Networking and Edge operating segment
R&D	Research and development
RSU	Restricted stock unit
SCIP	Semiconductor Co-Investment Program
SEC	US Securities and Exchange Commission
Smart Capital	Our Smart Capital approach accelerates progress on our IDM 2.0 strategy. This approach is designed to enable us to adjust quickly to opportunities in the market, while managing our margin structure and capital spending. The elements of Smart Capital include capacity investments, government incentives, customer commitments, continued use of external foundries.
SoC	A system on a chip, which integrates most of the components of a computer or other electronic system into a single silicon chip. We offer a range of SoC products in CCG, DCAI, and NEX. Our DCAI and NEX businesses offer SoCs across many market segments for a variety of applications, including products targeted for 5G base stations and network infrastructure
US	United States
US GAAP	US Generally Accepted Accounting Principles
VIE	Variable interest entity

Management's Discussion and Analysis

This report should be read in conjunction with our 2023 Form 10-K where we include additional information on our business, operating segments, risk factors, critical accounting estimates, policies, and the methods and assumptions used in our estimates, among other important information.

"Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements of this Form 10-Q provides additional information about our operating segments including the nature of segment revenues and expenses and reconciles our segment revenues presented below to our total consolidated net revenues, and our segment operating income (loss) presented below to our total consolidated operating income (loss), for each of the periods presented.

For additional key highlights of our results of operations, see "A Quarter in Review."

Intel Products


Intel Products consists substantially of design and development of CPUs and related solutions for third party customers. Intel Products is comprised of three operating segments: CCG, DCAI, and NEX.

Financial Performance

Intel Products Operating Segments Revenue \$B



Intel Products Segments Operating Income \$B



Operating Segments Revenue and Segments Operating Income Summary

Q2 2024 vs. Q2 2023

Total Intel Products revenue was \$11.8 billion in Q2 2024 and \$11.3 billion in Q2 2023. Revenue increased in Q2 2024 due to our CCG operating segment. Total Intel Products operating income increased to \$2.9 billion, or 25% operating margin in Q2 2024 from \$2.5 billion, or 22% operating margin in Q2 2023. This Q2 2024 operating margin increase is primarily due to higher Q2 2024 CCG revenue, lower Q2 2024 DCAI and NEX period charges due to the sell-through of previously reserved inventory and lower reserves taken, partially offset by higher Q2 2024 unit costs and higher Q2 2024 operating expenses in DCAI.

YTD 2024 vs. YTD 2023

Total Intel Products revenue was \$23.7 billion in YTD 2024 and \$21.5 billion in YTD 2023. Revenue increased in YTD 2024 primarily due to our CCG operating segment. Total Intel Products operating income increased to \$6.2 billion, or 26% operating margin for YTD 2024 from \$3.7 billion, or 17% operating margin in YTD 2023. This YTD 2024 operating margin increase is primarily due to higher YTD 2024 CCG revenue, lower YTD 2024 period charges across each of the Intel Products' operating segments due to the sell-through of previously reserved inventory and lower reserves taken, partially offset by higher YTD 2024 unit costs in CCG and DCAI.

Client Computing Group

We are committed to advancing PC experiences by delivering an annual cadence of leadership products and deepening our relationships with industry partners to co-engineer and deliver leading platform innovation. We engage in an intentional effort to bring together the operating system, system architecture, hardware, and software application integration to enable industry-leading PC experiences. We embrace these opportunities by focusing our roadmap, delivering innovative PC capabilities, and designing advanced PC experiences. By doing this, we believe we help continue to fuel innovation across the industry, providing a solid source of IP, scale, and cash flow for Intel.

Financial Performance



Operating Segment Revenue Summary

Q2 2024 vs. Q2 2023

- Notebook revenue was \$4.5 billion, up \$584 million from Q2 2023. Notebook volume increased 11% in Q2 2024 as customer inventory levels improved compared to higher levels in Q2 2023. Notebook ASPs increased 4% in Q2 2024 primarily driven by the ramp of newly introduced products based upon Intel 4 process technology and a lower mix of small core products, partially offset by a higher mix of older generation products.
- Desktop revenue was \$2.5 billion, up \$157 million from Q2 2023. Desktop volume increased 11% in Q2 2024 as customer inventory levels improved compared to higher levels in Q2 2023. Desktop ASPs decreased 4% in Q2 2024 primarily driven by a higher mix of older generation products.
- Other revenue was \$403 million, down \$111 million from Q2 2023 primarily driven by the exit of legacy businesses.

YTD 2024 vs. YTD 2023

- Notebook revenue was \$9.2 billion, up \$1.9 billion from YTD 2023. Notebook volume increased 24% in YTD 2024 as customer inventory levels improved compared to higher levels in YTD 2023. Notebook ASPs increased 2% in YTD 2024 primarily driven by the ramp of newly introduced products based upon Intel 4 process technology and a lower mix of small core products, partially offset by a higher mix of older generation products.
- Desktop revenue was \$5.0 billion, up \$739 million from YTD 2023. Desktop volume increased 19% in YTD 2024, as customer inventory levels improved compared to higher levels in YTD 2023. Desktop ASPs were roughly flat with YTD 2023.
- Other revenue was \$794 million, down \$201 million from YTD 2023 primarily driven by the exit of legacy businesses.

Segment Operating Income Summary

Operating income increased 26% from Q2 2023, with an operating margin of 34% in Q2 2024.

Operating income increased 62% from YTD 2023, with an operating margin of 34% in YTD 2024.

(In Millions)

\$	2,497	Q2 2024 Operating Income
	422	Higher product profit primarily from higher notebook and desktop revenue
	89	Other
\$	1,986	Q2 2023 Operating Income
\$	5,142	YTD 2024 Operating Income
	1,428	Higher product profit primarily from higher notebook and desktop revenue
	391	Lower period charges primarily driven by lower inventory reserves taken, higher sell-through of previously reserved inventory, and the exit of legacy businesses
	235	Lower operating expenses driven by various cost-cutting measures
	(198)	Higher unit cost primarily from increased mix of Intel 4 and Intel 7 products
	120	Other
\$	3,166	YTD 2023 Operating Income

Data Center and AI

DCAI delivers cutting-edge workload-optimized solutions to cloud service providers and enterprises, along with silicon devices for communications service providers, network and edge, and HPC customers. Our unique capabilities enable us to help solve our customers' most complex challenges with the depth and breadth of our hardware and software portfolio, advanced packaging, and at-scale manufacturing made possible through a resilient, global supply chain. Our global customers and partners encompass cloud hyperscalers, multinational corporations, small-and medium-sized enterprises, independent software vendors, systems integrators, communications service providers, and governments.

Financial Performance



Operating Segment Revenue Summary

Q2 2024 vs. Q2 2023

Revenue was \$3.0 billion, down \$110 million from Q2 2023, driven by a decrease in server revenue. Server volume decreased 22% in Q2 2024 due to lower demand in a competitive environment and a higher mix of high core count products. Server ASPs increased 23% in Q2 2024 primarily due to a lower mix of hyperscale customer-related revenue and a higher mix of high core count products.

YTD 2024 vs. YTD 2023

Revenue was \$6.1 billion, up \$25 million from YTD 2023, driven by an increase in server revenue. Server ASPs increased 24% in YTD 2024 primarily due to a lower mix of hyperscale customer-related revenue and a higher mix of high core count products. Server volume decreased 18% in YTD 2024 due to lower demand in a competitive environment and a higher mix of high core count products.

Segment Operating Income Summary

Operating income decreased 41% from Q2 2023, with an operating margin of 9% in Q2 2024.

Operating income increased 54% from YTD 2023, with an operating margin of 12% in YTD 2024.

(In Millions)

\$	276	Q2 2024 Operating Income
(293)		Higher server unit cost primarily driven by an increased mix of Intel 7 products
(185)		Higher operating expenses primarily driven by increased investments in leadership products
212		Lower period charges primarily driven by the sell-through of previously reserved inventory and lower reserves taken
73		Other
\$	469	Q2 2023 Operating Income
\$	758	YTD 2024 Operating Income
503		Lower period charges primarily driven by the sell-through of previously reserved inventory and lower reserves taken
431		Higher product profit on higher ASPs, net of reduced profit on lower volumes
(570)		Higher server unit cost primarily driven by an increased mix of Intel 7 products
(224)		Higher operating expenses primarily driven by increased product development costs
127		Other
\$	491	YTD 2023 Operating Income

Network & Edge

NEX lifts the world's networks and edge compute systems from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. We work with partners and customers to deliver and deploy intelligent edge platforms that allow software developers to achieve agility and to drive automation using AI for efficient operations while securing the integrity of their data at the edge. We have a broad portfolio of hardware and software platforms, tools, and ecosystem partnerships for the rapid digital transformation happening from the cloud to the edge. We are leveraging our core strengths in process, software, and manufacturing at scale to grow traditional markets and to accelerate entry into emerging ones.

Financial Performance



Operating Segment Revenue Summary

Q2 2024 vs. Q2 2023 and YTD 2024 vs. YTD 2023

Revenue was \$1.3 billion, down \$20 million from Q2 2023, and YTD 2024 revenue was \$2.7 billion, down \$145 million from YTD 2023. The revenue decreases in Q2 2024 and YTD 2024 were primarily due to 5G customers tempering purchases to reduce existing inventories, partially offset by higher Edge and Network revenue.

Segment Operating Income (Loss) Summary

Operating income increased 117% from Q2 2023, with an operating margin of 10% in Q2 2024.

Operating income increased \$328 million from YTD 2023, with an operating margin of 12% in YTD 2024.

(In Millions)

\$	139	Q2 2024 Operating Income
	75	Lower period charges primarily driven by the sell-through of previously reserved inventory
\$	64	Q2 2023 Operating Income
\$	323	YTD 2024 Operating Income (Loss)
	255	Lower period charges primarily driven by the sell-through of previously reserved inventory and lower reserves taken
	73	Other
\$	(5)	YTD 2023 Operating Income (Loss)

Intel Foundry

Intel Foundry, comprising our Foundry Technology Development, Foundry Manufacturing and Supply Chain, and Foundry Services organizations, is on a mission to deliver the best systems foundry capabilities to our customers and reshape the world's semiconductor industry. As the stewards of Moore's law, we continually innovate and advance world-class silicon process and advanced packaging technologies for customers. Our systems foundry offerings are strengthened by a robust design ecosystem with key industry partners, our systems of chips capabilities, and our secure, resilient and more sustainable supply chain. Our systems foundry is built on the foundation of our silicon process and advanced packaging technology offerings and enables co-optimized solutions for our customers in the AI era. We are strengthening the resilience of the global semiconductor supply chain for leading-edge and mature node semiconductor products by investing in geographically balanced and more sustainable manufacturing capacity. As a systems foundry for the AI era, Intel Foundry brings together these critical components to help our global customers drive the next phase of technology innovation.

Financial Performance



Operating Segment Revenue Summary

Q2 2024 vs. Q2 2023

Revenue was \$4.3 billion, up \$148 million from Q2 2023. Intersegment revenue was \$4.2 billion, up \$302 million from Q2 2023 driven by higher wafer volume primarily from Intel 3, Intel 4, and Intel 7 products, partially offset by lower intersegment ASPs and higher intersegment credits. External revenue was \$77 million, down \$154 million from Q2 2023 driven by lower traditional packaging services and equipment sales.

YTD 2024 vs. YTD 2023

Revenue was \$8.7 billion, down \$314 million from YTD 2023. Intersegment revenue was \$8.6 billion, down \$69 million from YTD 2023 driven by lower back end services revenue, lower intersegment ASPs, and higher intersegment credits in YTD 2024. These intersegment revenue decreases were partially offset by higher intersegment revenue from higher wafer volume primarily from Intel 3, Intel 4, and Intel 7 products. External revenue was \$104 million, down \$245 million from YTD 2023, driven by lower equipment sales and traditional packaging services.

Segment Operating Loss Summary

Operating loss was \$2.8 billion in Q2 2024, compared to an operating loss of \$1.9 billion in Q2 2023.

Operating loss was \$5.3 billion in YTD 2024, compared to an operating loss of \$4.2 billion in YTD 2023.

(In Millions)	
\$	Q2 2024 Operating Loss
(512)	Lower intersegment product and services profit primarily due to higher cost of production for Intel 4 and Intel 3 products, and lower external revenue
(373)	Higher period charges primarily related to factory start-up costs, costs associated with curtailing capacity on mature technology nodes and asset impairments
(320)	Higher operating expenses primarily driven by increased investments in process technology
244	Lower period charges related to excess capacity charges
\$ (1,869)	Q2 2023 Operating Loss
\$ (5,304)	YTD 2024 Operating Loss
(879)	Lower intersegment product and services profit primarily due to higher cost of production for Intel 4 and Intel 3 products, and lower external revenue
(530)	Higher period charges primarily related to factory start-up costs, costs associated with curtailing capacity on mature technology nodes and asset impairments
(386)	Higher operating expenses driven by increased investments in process technology
544	Lower period charges related to excess capacity charges
176	Lower period charges driven by lower intersegment inventory reserves taken
\$ (4,229)	YTD 2023 Operating Loss

All Other

Our "all other" category includes results of operations from our Altera and Mobileye businesses, from "other" non-reportable segments not otherwise presented, from start-up businesses that support our initiatives, and historical results of operations from divested businesses. Altera offers programmable semiconductors, primarily FPGAs, CPLDs, acceleration platforms, software, IP, and related products, for a broad range of applications across our embedded, communications, cloud, and enterprise market segments. Mobileye is a global leader in driving assistance and self-driving solutions, with a product portfolio designed to encompass the entire stack required for assisted and autonomous driving, including compute platforms, computer vision, and machine learning-based perception, mapping and localization, driving policy, and active sensors in development.

Financial Performance



Operating Segments Revenue and Segments Operating Income (Loss) Summary

Q2 2024 vs. Q2 2023

All other revenue was \$968 million, down \$451 million from Q2 2023. Altera revenue decreased \$487 million from Q2 2023, as customers tempered purchases to reduce existing inventories across all product lines. All other operating loss was \$35 million in Q2 2024 compared to operating income of \$355 million in Q2 2023 primarily due to lower Altera Q2 2024 revenue.

YTD 2024 vs. YTD 2023


All other revenue was \$1.7 billion, down \$1.1 billion from YTD 2023. Altera revenue decreased \$961 million from YTD 2023, as customers tempered purchases to reduce existing inventories across all product lines. Mobileye revenue decreased \$233 million from YTD 2023, as customers tempered purchases to reduce existing inventories of EyeQ™ products. All other operating loss was \$247 million compared to operating income of \$702 million in YTD 2023 due primarily to lower Altera and Mobileye YTD 2024 revenue.

Consolidated Condensed Results of Operations

(In Millions, Except Per Share Amounts)	Three Months Ended				Six Months Ended			
	Q2 2024		Q2 2023		YTD 2024		YTD 2023	
	Amount	% of Net Revenue	Amount	% of Net Revenue	Amount	% of Net Revenue	Amount	% of Net Revenue
Net revenue	\$ 12,833	100.0 %	\$ 12,949	100.0 %	\$ 25,557	100.0 %	\$ 24,664	100.0 %
Cost of sales	8,286	64.6 %	8,311	64.2 %	15,793	61.8 %	16,018	64.9 %
Gross margin	4,547	35.4 %	4,638	35.8 %	9,764	38.2 %	8,646	35.1 %
Research and development	4,239	33.0 %	4,080	31.5 %	8,621	33.7 %	8,189	33.2 %
Marketing, general, and administrative	1,329	10.4 %	1,374	10.6 %	2,885	11.3 %	2,677	10.9 %
Restructuring and other charges	943	7.3 %	200	1.5 %	1,291	5.1 %	264	1.1 %
Operating income (loss)	(1,964)	(15.3)%	(1,016)	(7.8)%	(3,033)	(11.9)%	(2,484)	(10.1)%
Gains (losses) on equity investments, net	(120)	(0.9)%	(24)	(0.2)%	85	0.3 %	145	0.6 %
Interest and other, net	80	0.6 %	224	1.7 %	225	0.9 %	365	1.5 %
Income (loss) before taxes	(2,004)	(15.6)%	(816)	(6.3)%	(2,723)	(10.7)%	(1,974)	(8.0)%
Provision for (benefit from) taxes	(350)	(2.7)%	(2,289)	(17.7)%	(632)	(2.5)%	(679)	(2.8)%
Net income (loss)	(1,654)	(12.9)%	1,473	11.4 %	(2,091)	(8.2)%	(1,295)	(5.3)%
Less: Net income (loss) attributable to non-controlling interests	(44)	(0.3)%	(8)	(0.1)%	(100)	(0.4)%	(18)	(0.1)%
Net income (loss) attributable to Intel	\$ (1,610)	(12.5)%	\$ 1,481	11.4 %	\$ (1,991)	(7.8)%	\$ (1,277)	(5.2)%
Earnings (loss) per share attributable to Intel—diluted	\$ (0.38)		\$ 0.35		\$ (0.47)		\$ (0.31)	

Consolidated Revenue

Consolidated Revenue Walk \$B¹



Q2 2024 vs. Q2 2023

Our Q2 2024 revenue was \$12.8 billion, down \$116 million from Q2 2023. CCG revenue increased 9% from Q2 2023 primarily due to higher notebook and desktop volumes as customer inventory levels improved compared to higher levels in Q2 2023. Notebook ASPs increased from Q2 2023 primarily driven by the ramp of newly introduced products based upon Intel 4 process technology and a lower mix of small core products, partially offset by an increased mix of older generation products. Desktop ASPs decreased from Q2 2023 primarily driven by a higher mix of older generation products. DCAI revenue decreased 3% from Q2 2023 due to lower server volume from lower demand in a competitive environment, partially offset by increased server ASPs primarily due to a lower mix of hyperscale customer-related revenue and a higher mix of high core count products. NEX revenue was roughly flat with Q2 2023. External Intel Foundry revenue decreased 67% from Q2 2023 due to lower traditional packaging services and equipment sales. Altera revenue decreased 57% from Q2 2023 as customers tempered purchases to reduce existing inventories across product lines.

Our Q2 2024 revenue was unfavorably impacted by the revocation of certain licenses for exports of consumer-related items to a customer in China.

Incentives offered to certain customers to accelerate purchases and to strategically position our products with customers for market segment share purposes, particularly in CCG, contributed approximately \$1.3 billion to our revenue during Q2 2024. The impacts of these Q2 2024 incentives were contemplated in our financial guidance for Q3 2024, as included in our Form 8-K dated August 1, 2024.

YTD 2024 vs. YTD 2023

Our YTD 2024 revenue was \$25.6 billion, up \$893 million or 4% from YTD 2023. CCG revenue increased 19% from YTD 2023 primarily due to higher notebook and desktop volumes as customer inventory levels improved compared to higher levels in YTD 2023. Notebook ASPs increased from YTD 2023 primarily driven by the ramp of newly introduced products based upon Intel 4 process technology and a lower mix of small core products, partially offset by an increased mix of older generation products. Desktop ASPs were roughly flat with YTD 2023. DCAI revenue was roughly flat with YTD 2023 as server ASPs increased primarily due to a lower mix of hyperscale customer-related revenue and a higher mix of high core count products, offset primarily by lower server volume from lower demand in a competitive environment. NEX revenue decreased 5% from YTD 2023 primarily due to 5G customers tempering purchases to reduce existing inventories, partially offset by higher Edge and Network revenue. Altera revenue decreased 58% from YTD 2023 as customers tempered purchases to reduce existing inventories across all product lines and Mobileye revenue decreased 26% from YTD 2023 as customers tempered purchases to reduce existing inventories across EyeQ products. External Intel Foundry revenue decreased 70% from YTD 2023 due to lower equipment sales and traditional packaging services.

¹ Excludes intersegment revenue

Consolidated Gross Margin

We derived a majority of our overall gross margin in Q2 2024 and in YTD 2024 from our Intel Products business sales through our CCG, DCAI, and NEX operating segments. Our overall gross margin dollars in Q2 2024 decreased by \$91 million, or 2%, compared to Q2 2023, and YTD 2024 increased by \$1.1 billion, or 13%, compared to YTD 2023.

Consolidated Gross Margin \$B¹

(Percentages in chart indicate gross margin as a percentage of total revenue)




(In Millions)

\$	Q2 2024 Gross Margin
(651)	Higher unit cost primarily from increased mix of Intel 4 and Intel 7 products
(418)	Lower product profit primarily from lower Altera revenue
(317)	Higher period charges primarily related to factory start-up costs, costs associated with curtailing capacity on mature technology nodes and asset impairments
574	Higher product profit primarily from higher notebook and desktop revenue
353	Lower period charges driven by the sell-through of previously reserved inventory and lower reserves taken
244	Lower period charges related to excess capacity charges
124	Other
\$ 4,547	Q2 2023 Gross Margin
\$	YTD 2024 Gross Margin
2,089	Higher product profit primarily from higher notebook and desktop revenue and higher server ASPs, net of reduced profit on lower server volumes
906	Lower period charges driven by the sell-through of previously reserved inventory and lower reserves taken
544	Lower period charges related to excess capacity charges
(982)	Lower product profit primarily from lower Altera and Mobileye revenue
(968)	Higher unit cost primarily from increased mix of Intel 4 and Intel 7 products
(530)	Higher period charges primarily related to factory start-up costs, costs associated with curtailing capacity on mature technology nodes and asset impairments
59	Other
\$ 8,646	YTD 2023 Gross Margin

¹ Excludes intersegment activity

Operating Expenses

Total R&D and MG&A expenses for Q2 2024 were \$5.6 billion, up 2% from Q2 2023, and \$11.5 billion for YTD 2024, up 6% from YTD 2023. These expenses represent 43.4% of revenue for Q2 2024 and 42.1% of revenue for Q2 2023, and 45.0% of revenue for YTD 2024 and 44.1% of revenue for YTD 2023. In support of our strategy, described in our 2023 Form 10-K, we continue to make significant investments to accelerate our process technology roadmap. This requires continued investments in R&D and focused efforts to attract and retain talent. We expect total R&D and MG&A expenses to be reduced as we implement planned cost-reduction measures, including reductions in headcount and other operating expenditures, designed to accelerate profitable growth, enable further operational efficiency and agility, and create capacity for sustained investment in technology and manufacturing leadership.



Research and Development

Q2 2024 vs. Q2 2023

R&D increased by \$159 million, or 4%, driven by the following:

- + Investments in our process technology and leadership products
- Lower share-based compensation and incentive-based cash compensation

YTD 2024 vs. YTD 2023

R&D increased by \$432 million, or 5%, driven by the following:

- + Investments in our process technology and leadership products
- + Higher share-based compensation
- Lower incentive-based cash compensation
- The effects of various cost cutting measures

Marketing, General, and Administrative

Q2 2024 vs. Q2 2023

MG&A decreased by \$45 million, or 3%, driven by the following:

- Lower share-based compensation and incentive-based cash compensation
- + Increase in corporate spending, primarily driven by our IDM 2.0 transformation

YTD 2024 vs. YTD 2023

MG&A increased by \$208 million, or 8%, driven by the following:

- + Increase in corporate spending, primarily driven by our IDM 2.0 transformation and higher marketing expenses
- + Higher share-based compensation
- Lower incentive-based cash compensation

Restructuring and Other Charges

(In Millions)	Q2 2024	Q2 2023	YTD 2024	YTD 2023
Employee severance and benefit arrangements	\$ 165	\$ 171	\$ 294	\$ 132
Litigation charges and other	778	20	778	97
Asset impairment charges	—	9	219	35
Total restructuring and other charges	\$ 943	\$ 200	\$ 1,291	\$ 264

Employee severance and benefit arrangements includes charges of \$294 million in YTD 2024 relating to actions taken to streamline operations and to reduce costs.

Litigation charges and other includes a charge of \$780 million in Q2 2024 arising out of the R2 litigation. Refer to "Note 13: Contingencies" within Notes to Consolidated Condensed Financial Statements for further information on legal proceedings.

Asset impairment charges includes a goodwill impairment loss of \$222 million in Q1 2024 related to our Intel Foundry reporting unit. Refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for further information.

Gains (Losses) on Equity Investments and Interest and Other, Net

(In Millions)	Q2 2024	Q2 2023	YTD 2024	YTD 2023
Ongoing mark-to-market adjustments on marketable equity securities	\$ (43)	\$ (85)	\$ (134)	\$ 103
Observable price adjustments on non-marketable equity securities	25	—	49	10
Impairment charges	(91)	(38)	(159)	(74)
Sale of equity investments and other	(11)	99	329	106
Total gains (losses) on equity investments, net	\$ (120)	\$ (24)	\$ 85	\$ 145
Interest and other, net	\$ 80	\$ 224	\$ 225	\$ 365

In Q2 2024, impairments and ongoing mark-to-market losses for our interest in Montage Technology Co., were partially offset by ongoing mark-to-market gains for other marketable equity securities. For YTD 2024, we recognized a \$336 million initial fair value adjustment within *sale of equity investments and other* upon Astera Labs, Inc. shares becoming marketable, which was partially offset by impairments and ongoing mark-to-market losses for our interest in Montage Technology Co.

YTD 2023 gains were primarily driven by our interest in Montage Technology Co., Ltd and others.

Provision for (Benefit from) Taxes

(In Millions)	Q2 2024	Q2 2023	YTD 2024	YTD 2023
Income (loss) before taxes	\$ (2,004)	\$ (816)	\$ (2,723)	\$ (1,974)
Provision for (benefit from) taxes	\$ (350)	\$ (2,289)	\$ (632)	\$ (679)
Effective tax rate	17.5 %	280.5 %	23.2 %	34.4 %

In Q2 2024, we recognized a benefit from taxes as we applied our year-to-date actual effective tax rate to our year-to-date measure of ordinary income (loss) before taxes, which reflects our jurisdictional mix of ordinary income and losses. Benefit from taxes in Q2 2023 represented the year-to-date true-up adjustment when the actual effective tax rate approach was adopted starting in the second quarter of 2023. Our effective tax rate decreased in YTD 2024 compared to YTD 2023, primarily driven by a higher proportion of our income being taxed in non-US jurisdictions, and our R&D tax credits which provide a tax benefit based on our eligible R&D spending and are not dependent on income before taxes.

Our benefit from income taxes was determined using the actual effective tax rate, adjusted for discrete items, for all periods presented due to the variability of the rate as a result of fluctuations in forecasted income and the effects of being taxed in multiple tax jurisdictions. We use the actual effective tax rate for the year-to-date period, adjusted for discrete items, if any, under certain circumstances where we are unable to make a reliable estimate of the annual effective tax rate.

Liquidity and Capital Resources

We consider the following when assessing our liquidity and capital resources:

(In Millions)	Jun 29, 2024	Dec 30, 2023
Cash and cash equivalents	\$ 11,287	\$ 7,079
Short-term investments	17,986	17,955
Total cash and short-term investments	\$ 29,273	\$ 25,034
Total debt	\$ 53,029	\$ 49,266

We believe we have sufficient sources of funding to meet our business requirements for the next 12 months and in the longer term. Cash generated by operations, and total cash and short-term investments as shown in the preceding table, are our primary sources of liquidity for funding our strategic business requirements. These sources are further supplemented by our committed credit facilities and other borrowing capacity and certain other Smart Capital initiatives that we have undertaken, including our Ireland SCIP transaction that closed in the second quarter of 2024 that resulted in \$11.0 billion of net cash inflows to us. Refer to "Note 3: Non-Controlling Interests" within Notes to Consolidated Condensed Financial Statements for further information. Our short-term funding requirements include capital expenditures for worldwide manufacturing and assembly and test, including investments in our process technology roadmap; working capital requirements; potential acquisitions, strategic investments, and dividends. We expect reductions in operating expenditures, capital expenditures, and cost of sales as we implement cost-reduction measures, including reductions in headcount, designed to accelerate profitable growth, enable further operational efficiency and agility, and create capacity for sustained investment in technology and manufacturing leadership. Our long-term funding requirements incrementally contemplate investments in significant manufacturing expansion plans and investments to accelerate our process technology.

Our total cash and short-term investments and related cash flows may be affected by certain discretionary actions we may take with customers and suppliers to accelerate or delay certain cash receipts or payments to manage liquidity for our strategic business requirements. These actions can include, among others, negotiating with suppliers to optimize our payment terms and conditions, adjusting the timing of cash flows associated with customer sales programs and collections, managing inventory levels and purchasing practices, and selling certain of our accounts receivables on a non-recourse basis to third party financial institutions.

We expect to continue to benefit from government incentives, and any incentives above our current expectations would enable us to increase the pace and size of our IDM 2.0 investments. Conversely, incentives below our expectations would increase our anticipated cash requirements and/or potentially curtail planned investments.

In July 2024 our Board of Directors declared a quarterly dividend of \$0.125 per share on the company's common stock, which will be payable on September 1, 2024, to stockholders of record as of August 7, 2024. On August 1, 2024, we announced our Board of Directors suspended the declaration of quarterly dividends on our common stock starting with Q4 2024, recognizing the importance of prioritizing liquidity to support the investments needed to execute our strategy. The Board of Directors reiterated our long-term commitment to a competitive dividend as cash flows improve to sustainably higher levels.

In the first half of 2024, we issued a total of \$2.6 billion aggregate principal amount of senior notes and remarketed \$438 million aggregate principal amount of other bonds for general corporate purposes, including, but not limited to, refinancing of outstanding debt and funding for working capital and capital expenditures. We also expanded both our 5-year \$5.0 billion revolving credit facility agreement and our 364-day \$5.0 billion credit facility agreement, to \$7.0 billion and \$8.0 billion, respectively, and the maturity dates were extended to February 2029 and January 2025, respectively. We have other potential sources of liquidity including our commercial paper program and our automatic shelf registration statement on file with the SEC, pursuant to which we may offer an unspecified amount of debt, equity, and other securities. Under our commercial paper program, we have an ongoing authorization from our Board of Directors to borrow up to \$10.0 billion. As of June 29, 2024, we had \$3.2 billion of commercial paper obligations outstanding and no outstanding borrowings on the revolving credit facilities. Refer to "Note 10: Borrowings" within Notes to Consolidated Condensed Financial Statements for further information.

We maintain a diverse investment portfolio that we continually analyze based on issuer, industry, and country. Substantially all of our investments in debt instruments were in investment-grade securities.

Cash flows from operating, investing and financing activities were as follows:

(In Millions)	Six Months Ended	
	Jun 29, 2024	Jul 1, 2023
Net cash provided by (used for) operating activities	\$ 1,069	\$ 1,023
Net cash provided by (used for) investing activities	(11,728)	(11,329)
Net cash provided by (used for) financing activities	14,867	7,511
Net increase (decrease) in cash and cash equivalents	\$ 4,208	\$ (2,795)

Operating Activities

Operating cash flows consist of net income (loss) adjusted for certain non-cash items and changes in certain assets and liabilities.

Cash provided by operations in the first six months of 2024 was roughly flat compared to the first six months of 2023 as we incurred a higher net loss that was offset by more favorable operating cash flow adjustments in the first six months of 2024 relative to the first six months of 2023.

Investing Activities

Investing cash flows consist primarily of capital expenditures; investment purchases, sales, maturities, and disposals; and proceeds from capital-related government incentives.

Cash used for investing activities was higher in the first six months of 2024 compared to the first six months of 2023, primarily due to a reduction in cash flows from the sales and maturities of short-term investments, net of purchases, and certain other cash unfavorable investing activities during the first six months of 2024. These cash unfavorable movements in the first six months of 2024 were partially offset by lower capital additions and greater proceeds from capital related incentives during the first six months of 2024 relative to the first six months of 2023.

Financing Activities

Financing cash flows consist primarily of proceeds from strategic initiatives including partner contributions and equity-related issuances, issuance and repayment of short-term and long-term debt, and payment of dividends to stockholders.

Cash provided by financing activities was higher in the first six months of 2024 compared to the first six months of 2023, primarily due to higher SCIP partner contributions and reduced dividend payments. These activities were partially offset by a reduction in proceeds from our debt and commercial paper issuances, net of debt and commercial paper repayments; and the absence of proceeds from sales of subsidiary shares in the first six months of 2024 compared to proceeds in the first six months of 2023.

Non-GAAP Financial Measures

In addition to disclosing financial results in accordance with US GAAP, this document contains references to the non-GAAP financial measures below. We believe these non-GAAP financial measures provide investors with useful supplemental information about our operating performance, enable comparison of financial trends and results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business and measuring our performance. These non-GAAP financial measures are used in our performance-based RSUs and our cash bonus plans.

Our non-GAAP financial measures reflect adjustments based on one or more of the following items, as well as the related income tax effects. Income tax effects are calculated using a fixed long-term projected tax rate of 13% across all adjustments. We project this long-term non-GAAP tax rate on at least an annual basis using a five-year non-GAAP financial projection that excludes the income tax effects of each adjustment. The projected non-GAAP tax rate also considers factors such as our tax structure, our tax positions in various jurisdictions, and key legislation in significant jurisdictions where we operate. This long-term non-GAAP tax rate may be subject to change for a variety of reasons, including the rapidly evolving global tax environment, significant changes in our geographic earnings mix, or changes to our strategy or business operations. Management uses this non-GAAP tax rate in managing internal short- and long-term operating plans and in evaluating our performance; we believe this approach facilitates comparison of our operating results and provides useful evaluation of our current operating performance.

Our non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with US GAAP, and the financial results calculated in accordance with US GAAP and reconciliations from these results should be carefully evaluated.

Non-GAAP adjustment or measure	Definition	Usefulness to management and investors
Acquisition-related adjustments	Amortization of acquisition-related intangible assets consists of amortization of intangible assets such as developed technology, brands, and customer relationships acquired in connection with business combinations. Charges related to the amortization of these intangibles are recorded within both cost of sales and MG&A in our US GAAP financial statements. Amortization charges are recorded over the estimated useful life of the related acquired intangible asset, and thus are generally recorded over multiple years.	We exclude amortization charges for our acquisition-related intangible assets for purposes of calculating certain non-GAAP measures because these charges are inconsistent in size and are significantly impacted by the timing and valuation of our acquisitions. These adjustments facilitate a useful evaluation of our current operating performance and comparison to our past operating performance and provide investors with additional means to evaluate cost and expense trends.
Share-based compensation	Share-based compensation consists of charges related to our employee equity incentive plans.	We exclude charges related to share-based compensation for purposes of calculating certain non-GAAP measures because we believe these adjustments provide comparability to peer company results and because these charges are not viewed by management as part of our core operating performance. We believe these adjustments provide investors with a useful view, through the eyes of management, of our core business model, how management currently evaluates core operational performance, and additional means to evaluate expense trends, including in comparison to other peer companies.
Restructuring and other charges	Restructuring charges are costs associated with a restructuring plan and are primarily related to employee severance and benefit arrangements. Other charges include periodic goodwill and asset impairments, and costs associated with restructuring activity. Q2 2024 includes a charge arising out of the R2 litigation.	We exclude restructuring and other charges, including any adjustments to charges recorded in prior periods, for purposes of calculating certain non-GAAP measures because these costs do not reflect our core operating performance. These adjustments facilitate a useful evaluation of our core operating performance and comparisons to past operating results and provide investors with additional means to evaluate expense trends.
(Gains) losses on equity investments, net	(Gains) losses on equity investments, net consists of ongoing mark-to-market adjustments on marketable equity securities, observable price adjustments on non-marketable equity securities, related impairment charges, and the sale of equity investments and other.	We exclude these non-operating gains and losses for purposes of calculating certain non-GAAP measures because it provides comparability between periods. The exclusion reflects how management evaluates the core operations of the business.

(Gains) losses from divestiture	(Gains) losses are recognized at the close of a divestiture, or over a specified deferral period when deferred consideration is received at the time of closing. Based on our ongoing obligation under the NAND wafer manufacturing and sale agreement entered into in connection with the first closing of the sale of our NAND memory business on December 29, 2021, a portion of the initial closing consideration was deferred and will be recognized between first and second closing.	We exclude gains or losses resulting from divestitures for purposes of calculating certain non-GAAP measures because they do not reflect our current operating performance. These adjustments facilitate a useful evaluation of our current operating performance and comparisons to past operating results.
Adjusted free cash flow	We reference a non-GAAP financial measure of adjusted free cash flow, which is used by management when assessing our sources of liquidity, capital resources, and quality of earnings. Adjusted free cash flow is operating cash flow adjusted for (1) additions to property, plant, and equipment, net of proceeds from capital-related government incentives and partner contributions, and (2) payments on finance leases.	This non-GAAP financial measure is helpful in understanding our capital requirements and sources of liquidity by providing an additional means to evaluate the cash flow trends of our business.

Following are the reconciliations of our most comparable US GAAP measures to our non-GAAP measures presented:

	Three Months Ended	
	Jun 29, 2024	Jul 1, 2023
Gross margin percentage	35.4 %	35.8 %
Acquisition-related adjustments	1.7 %	2.4 %
Share-based compensation	1.5 %	1.6 %
Non-GAAP gross margin percentage	38.7 %	39.8 %
Earnings (loss) per share attributable to Intel—diluted	\$ (0.38)	\$ 0.35
Acquisition-related adjustments	0.06	0.08
Share-based compensation	0.18	0.22
Restructuring and other charges	0.22	0.05
(Gains) losses on equity investments, net	0.03	0.01
(Gains) losses from divestiture	(0.01)	(0.01)
Adjustments attributable to non-controlling interest	—	—
Income tax effects	(0.08)	(0.57)
Non-GAAP earnings per share attributable to Intel—diluted	\$ 0.02	\$ 0.13
 (In Millions)		
Net cash provided by (used for) operating activities		
Net partner contributions and incentives received (cash expended) for property plant and equipment	\$ 1,069	\$ 1,023
Payments on finance leases	908	(12,418)
Adjusted free cash flow	—	(96)
	\$ 1,977	\$ (11,491)
Net cash provided by (used for) investing activities	\$ (11,728)	\$ (11,329)
Net cash provided by (used for) financing activities	\$ 14,867	\$ 7,511
 Six Months Ended		
Jun 29, 2024		
Jul 1, 2023		

Risk Factors and Other Key Information

Risk Factors

The risks described in "Risk Factors" within Other Key Information in our 2023 Form 10-K could materially and adversely affect our business, financial condition, and results of operations, and the trading price of our common stock could decline. These risk factors do not identify all risks that we face—our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. Refer also to the other information set forth in this Form 10-Q, including in the Forward-Looking Statements, MD&A, and the Consolidated Condensed Financial Statements and Supplemental Details sections.

Form 8-K Disclosable Events

On July 30, 2024, our Board of Directors approved the adoption of the Intel Corporation Executive Severance Plan, effective as of August 1, 2024. The plan provides that certain senior executives, including the company's named executive officers other than its CEO, are eligible to receive severance payments and benefits in the event of a termination of employment by the company without cause (as defined in the plan). Subject to the execution and non-revocation of a release of claims in favor of the company, such named executive officers are eligible to receive the following severance payments and benefits:

- a cash payment equal to 1.5 times the sum of base salary and target annual bonus opportunity, payable in installments over an 18-month period following termination of employment in accordance with the company's payroll practices;
- an additional lump sum payment approximately equal to 18 months of the monthly premium for participation in the company's group health plans;
- pro-rated vesting of eligible restricted stock units and eligible performance stock units based on the number of whole months of employment during the vesting period; provided that the vesting of time-based equity awards will accelerate at the time of termination of employment and performance-based equity awards will vest based on actual performance results at the end of the applicable performance period; and
- outplacement services at the company's expense for up to 18 months.

The foregoing summary of the plan does not purport to be complete and is qualified in its entirety by reference to the full text of the plan, a copy of which is filed as Exhibit 10.3 hereto.

Quantitative and Qualitative Disclosures About Market Risk

We are affected by changes in currency exchange and interest rates, as well as equity and commodity prices. Our risk management programs are designed to reduce, but may not entirely eliminate, the impacts of these risks. For a discussion about market risk and sensitivity analysis related to changes in currency exchange rates, interest rates, equity prices, and commodity prices refer to "Quantitative and Qualitative Disclosures About Market Risk" within MD&A in our 2023 Form 10-K.

Controls and Procedures

Inherent Limitations on Effectiveness of Controls

Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

Evaluation of Disclosure Controls and Procedures

Based on management's evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), were effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 29, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Issuer Purchases of Equity Securities

We have an ongoing authorization, originally approved by our Board of Directors in 2005 and subsequently amended, to repurchase shares of our common stock in open market or negotiated transactions. No shares were repurchased during the quarter ending June 29, 2024. As of June 29, 2024, we were authorized to repurchase up to \$110.0 billion, of which \$7.2 billion remained available.

We issue RSUs as part of our equity incentive plans. In our Consolidated Condensed Financial Statements, we treat shares of common stock withheld for tax purposes on behalf of our employees in connection with the vesting of RSUs as common stock repurchases because they reduce the number of shares that would have been issued upon vesting. These withheld shares of common stock are not considered common stock repurchases under our authorized common stock repurchase program.

Rule 10b5-1 Trading Arrangements

Our directors and officers (as defined in Rule 16a-1 under the Exchange Act) may from time to time enter into plans or other arrangements for the purchase or sale of our shares that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. During the quarter ended June 29, 2024, no such plans or arrangements were adopted or terminated, including by modification.

Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934

Section 13(r) of the Exchange Act requires an issuer to disclose certain information in its periodic reports if it or any of its affiliates knowingly engaged in certain activities, transactions, or dealings with individuals or entities subject to specific US economic sanctions during the reporting period, even when the activities, transactions, or dealings are conducted in compliance with applicable law. On March 2, 2021, the US Secretary of State designated the Federal Security Service of the Russian Federation (FSB) as a party subject to one such sanction. Though Intel has suspended sales in Russia, there may be a need to file documents or engage with FSB as Intel winds up our local Russian offices. All such dealings are explicitly authorized by General License 1B issued by the US Department of the Treasury's Office of Foreign Assets Control (OFAC), and there are no gross revenues or net profits directly associated with any such dealings by us with the FSB.

On April 15, 2021, the US Department of the Treasury designated Positiv Teknolodzhiz, AO (Positive Technologies), a Russian IT security firm, as a party subject to one of the sanctions specified in Section 13(r). Prior to the designation, we communicated with Positive Technologies regarding its IT security research and coordinated disclosure of security vulnerabilities identified by the firm. Based on a license issued by OFAC, we resumed such communications. There are no gross revenues or net profits directly associated with any such activities. We plan to continue these communications in accordance with the terms and conditions of the OFAC license.

Exhibits

Exhibit Number	Exhibit Description	Incorporated by Reference				Filed or Furnished Herewith
		Form	File Number	Exhibit	Filing Date	
3.1	<u>Corrected Third Restated Certificate of Incorporation of Intel Corporation, dated October 23, 2023</u>	10-Q	000-06217	3.1	10/27/2023	
3.2	<u>Intel Corporation Bylaws, as amended and restated on November 29, 2023</u>	8-K	000-06217	3.2	12/5/2023	
10.1	<u>Purchase and Sale Agreement, dated as of June 4, 2024, by and among Intel Ireland Limited, Grange Newco LLC, and AP Grange Holdings, LLC</u>	8-K	000-06217	10.1	6/4/2024	
10.2	<u>Form of Amended and Restated Limited Liability Company Agreement of Grange Newco LLC by and among Grange Newco LLC, Intel Ireland Limited and AP Grange Holdings, LLC</u>	8-K	000-06217	10.2	6/4/2024	
10.3 [†]	<u>Executive Severance Plan of Intel Corporation dated August 1, 2024</u>					X
31.1	<u>Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act</u>					X
31.2	<u>Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act</u>					X
32.1	<u>Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350</u>					X
101	Inline XBRL Document Set for the consolidated condensed financial statements and accompanying notes in Consolidated Condensed Financial Statements and Supplemental Details					X
104	Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101					X

[†] Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.

Form 10-Q Cross-Reference Index

Item Number	Item	
Part I - Financial Information		
Item 1.	Financial Statements	Pages <u>4</u> - <u>24</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations: Liquidity and capital resources Results of operations Critical accounting estimates	Pages <u>39</u> - <u>40</u> Pages <u>3</u> , <u>25</u> - <u>38</u> Page <u>25</u> Page <u>43</u>
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	Page <u>43</u>
Item 4.	Controls and Procedures	Page <u>43</u> - <u>44</u>
Part II - Other Information		
Item 1.	Legal Proceedings	Pages <u>20</u> - <u>24</u>
Item 1A.	Risk Factors	Page <u>43</u>
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	Page <u>44</u>
Item 3.	Defaults Upon Senior Securities	Not applicable
Item 4.	Mine Safety Disclosures	Not applicable
Item 5.	Other Information Form 8-K Disclosable Events Rule 10b5-1 Trading Arrangements Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934	Page <u>43</u> Page <u>44</u> Page <u>44</u> Page <u>45</u>
Item 6.	Exhibits	Page <u>47</u>
Signatures		

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEL CORPORATION
(Registrant)

Date: August 1, 2024

By: /s/ DAVID ZINSNER

David Zinsner
Executive Vice President, Chief Financial Officer, and
Principal Financial Officer

Date: August 1, 2024

By: /s/ SCOTT GAWEL

Scott Gawel
Corporate Vice President, Chief Accounting Officer, and
Principal Accounting Officer

**INTEL CORPORATION
EXECUTIVE SEVERANCE PLAN**

1. PURPOSE

The Intel Corporation Executive Severance Plan (this “Plan”) has been established by Intel Corporation (“Intel” or the “Company”) for the purposes of securing the continued service of certain senior executives of the Company and providing these executives with certain benefits in the event of a Covered Termination (as defined below).

2. DEFINITIONS

1. “Accrued Obligations” shall mean (i) the Participant’s base salary earned but unpaid through the date of termination, (ii) any accrued but unused vacation and sabbatical earned through the date of termination, if applicable, (iii) any unreimbursed expenses incurred through the date of termination (subject to submission by the Participant of supporting documentation by the date of termination) in accordance with Company policy, and (iv) any other amounts that are required to be paid, or to which the Participant is entitled, under any plan, contract, or arrangement of the Company as of the end of the Participant’s employment, excluding any severance or termination plans, policies, and arrangements.

2. “Board” shall mean the Board of Directors of the Company.

3. “Cause” shall mean the Participant’s (i) commission of an act of material fraud or dishonesty against the Company; (ii) intentional refusal or willful failure to substantially carry out the lawful and reasonable instructions of the Board or Intel’s Chief Executive Officer (other than any such failure resulting from the Participant’s disability); (iii) conviction of, or guilty plea or “no contest” plea to, a felony or conviction of, or guilty plea or “no contest” plea to, a misdemeanor involving moral turpitude; (iv) gross misconduct in connection with the performance of the Participant’s duties; (v) improper disclosure of confidential information or a material violation of a policy of the Company or the Company’s Code of Conduct; (vi) breach or misrepresentation under any intellectual property, invention assignment, confidentiality, or proprietary information agreement to which the Company is a party; (vii) failure to reasonably cooperate with the Company in any investigation or formal proceeding or being found liable in a Securities and Exchange Commission enforcement action or otherwise being disqualified from serving in the Participant’s job; or (viii) breach of duty of loyalty to the Company. Prior to termination for Cause, Intel shall provide thirty (30) days prior written notice of the grounds for Cause and give the Participant an opportunity within (and including all of) those thirty (30) days to cure the alleged breach. If the breach is substantially cured during such period, Cause shall not exist on account of such breach.

4. “COBRA” shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, and the rules, regulations, or other interpretive guidance promulgated thereunder, as well as any successor laws in replacement thereof.

5. “Code” shall mean the Internal Revenue Code of 1986, as such is amended from time to time, and any reference to a section of the Code shall include any successor provision of the Code.

6. “Committee” shall mean the Talent and Compensation Committee of the Board, or such other committee appointed by the Board to administer this Plan.

7. “Covered Termination” shall mean any termination of a Participant’s employment initiated by the Company or any of its Subsidiaries (other than an Excluded Subsidiary) other than for Cause. A Covered Termination does not include any termination due to the Participant’s death or disability nor any termination initiated by the Participant for any reason. A Covered Termination shall not occur solely as a result of (i) a transfer

of employment in which the Participant remains employed by the Company or one of its Subsidiaries (including an Excluded Subsidiary), or (ii) subject to the provisions of Section 13(a), the sale, transfer, or other disaffiliation of one or more Subsidiaries in which the Participant remains employed by the Company or the Subsidiary, or the transfer of employment of a Participant to a third party in connection with a sale, transfer, or other disaffiliation of the assets or business of the Company or any of its Subsidiaries. In the event a Participant's employment is transferred from the Company to an Excluded Subsidiary, the individual shall no longer be eligible to be a Participant in this Plan or receive any of the Severance Benefits as of the effective date of the transfer of employment, and such transfer of employment shall not be deemed a Covered Termination under this Plan.

8. "**Date of Termination**" shall mean the effective date of a Participant's Covered Termination.

9. "**Effective Date**" shall mean August 1, 2024.

10. "**Eligibility Date**" shall mean, with respect to each Participant, the date on which the employee was hired or promoted to a role that is eligible to be a Participant in this Plan. For all executives of the Company employed in a position on the Effective Date that makes the executive eligible to be a Participant, the Eligibility Date shall mean the Effective Date.

11. "**Eligible RSUs**" shall mean Intel restricted stock units awarded to a Participant (i) as part of the Participant's annual long-term incentive equity awards under an Equity Plan that are subject solely to time-based vesting and that were granted to the Participant (A) after the Participant's Eligibility Date and (B) more than one year prior to the Participant's Date of Termination, or (ii) as Make-Whole Awards that are subject solely to time-based vesting and that were granted to the Participant after the Participant's Eligibility Date, unless excluded in accordance with the requirements of the last sentence of Section 5(a) of this Plan.

12. "**Eligible PSUs**" shall mean Intel performance-based restricted stock units or performance stock units awarded to a Participant (i) as part of the Participant's annual long-term incentive equity awards under an Equity Plan that were granted to the Participant (A) after the Participant's Eligibility Date and (B) more than one year prior to the Participant's Date of Termination, or (ii) as Make-Whole Awards that were granted to the Participant after the Participant's Eligibility Date, unless excluded in accordance with the requirements of the last sentence of Section 5(a) of this Plan.

13. "**Equity Plans**" shall mean the Intel Corporation 2006 Equity Incentive Plan and the Intel Corporation 2021 Inducement Plan, each as amended, and any other current or future equity-based incentive plan or arrangement adopted by the Company, but excluding the Intel Corporation 2006 Employee Stock Purchase Plan or any other plan intended to be qualified under Code Section 423.

14. "**Excluded Employees**" shall mean any employees employed with an Excluded Subsidiary or employees with an agreement or offer letter in place on or after the Effective Date that provides that such employee is an executive of an Excluded Subsidiary or the employee's employment will be transferred to an Excluded Subsidiary.

15. "**Excluded Subsidiaries**" shall mean the Subsidiaries (and any subsidiaries thereof) set forth on Exhibit B.

16. "**ERISA**" shall mean the Employee Retirement Income Security Act of 1974, as amended.

17. "**Make-Whole Awards**" shall mean Intel restricted stock units or performance stock units granted to a Participant under an Equity Plan at the time the Participant was hired that are designated by the Company as "Make-Whole" awards.

18. "**Outplacement Period**" shall mean the period following a Participant's Date of Termination for which the applicable Participant is eligible for outplacement services, with the duration as set forth on Exhibit A.

19. "**Participant**" shall mean any employee of the Company or its Subsidiaries, other than an Excluded Subsidiary, whose position is designated by the Company as grade 14 through 17, other than the Excluded Employees or as otherwise determined by the Committee.

20. "**Plan**" means this Intel Corporation Executive Severance Plan, as amended from time to time.

21. "**Severance Multiplier**" shall mean the multiplier applicable to a Participant as set forth on Exhibit A.

22. "**Severance Period**" shall mean the period following a Participant's Date of Termination with a duration set forth on Exhibit A.

23. "**Subsidiary**" shall mean any corporation or entity in which Intel owns or controls, directly or indirectly, fifty percent (50%) or more of the voting power or economic interests of such corporation or entity.

24. "**Target Annual Bonus Opportunity**" shall mean the Participant's target annual cash bonus opportunity as in effect for the year in which the Participant's termination of employment occurs.

25. "**Termination Arrangement**" shall mean, other than this Plan, any agreement or contract with the Company or any Subsidiary thereof, or any plan, policy, program, or other arrangement adopted or established by the Company or a Subsidiary or under the WARN Act or other applicable law providing for payments from the Company or its Subsidiaries due to a termination of employment.

26. "**WARN Act**" shall mean the federal Worker Adjustment and Retraining Notification Act and any other comparable law applicable under the laws of any state or foreign jurisdiction.

3. ADMINISTRATION

1. This Plan shall be administered by the Committee in its sole and absolute discretion, and all determinations by the Committee shall be final, binding, and conclusive on all parties and be given the maximum possible deference allowed by law. In the event of any conflict or inconsistency between another document and the terms of this Plan, the terms and conditions of this Plan shall govern and control.

2. The Committee shall have the authority, consistent with the terms of this Plan, to (i) determine the terms and conditions relating to the Severance Benefits (defined below), if any, (ii) interpret, administer, reconcile any inconsistency, correct any defect, and/or supply any omission in this Plan, (iii) establish, amend, suspend, or waive any rules and procedures with respect to this Plan, and (iv) make any other determination and take any other action that the Committee deems necessary or desirable for administration of this Plan, including, without limitation, the timing and amount of payments.

4. SEVERANCE BENEFITS

In the event of a termination of a Participant's employment for any reason, the Company shall pay the Participant the Accrued Obligations on or as soon as administratively practicable after the Participant's date of termination of employment, if not theretofore paid or provided. In addition, subject to Section 6 of this Plan, in the event of a Participant's Covered Termination, in addition to payment of the Accrued Obligations, the Participant shall be eligible to receive the "**Severance Benefits**" provided in this Section 4:

a. Payment of an amount equal to the product of (i) the Participant's Severance Multiplier, and (ii) the sum of the Participant's (A) annual base salary at the rate in effect as of the Date of Termination, and (B) the Participant's Target Annual Bonus Opportunity (the "**Cash Severance Payment**"). Except as otherwise provided in Section 9 below, the Cash Severance Payment shall be paid in equal installments over the Severance Period in accordance with the Company's regular payroll practices; provided that the payments shall commence on the Company's first regularly scheduled payroll date following the effective date of the Release (as defined in Section 6 below), with any installments otherwise scheduled to be paid to the Participant prior to such date instead paid to the Participant in a

lump-sum on such first payroll date; provided, further, that if the time period for the Participant to execute the Release and/or for it to become effective spans two (2) calendar years, the first payment will commence no earlier than the first regularly scheduled payroll date in the second calendar year (inclusive of any amounts that were otherwise scheduled to be paid prior thereto).

b. Payment of an amount equal to the product of (i) the number of months in the Participant's Severance Period and (ii) the amount equivalent to the monthly COBRA premium payments (as reasonably determined by the Committee) that would be payable by the Participant to continue the Participant's (and covered dependents', if any) Company-provided medical, dental, and/or vision coverage existing as of the Participant's Date of Termination. This payment shall be paid to the Participant on the same date the Participant is paid the first installment of the Cash Severance Payment under Section 4(a) above.

c. Prorated vesting as of the Participant's Date of Termination of any outstanding and unvested award of Eligible RSUs held by a Participant on the Participant's Date of Termination, with the number of Eligible RSUs vesting determined by multiplying (i) the number of unvested Eligible RSUs as of the Participant's Date of Termination by (ii) a fraction, the numerator of which is the number of full months the Participant was employed by the Company or any of its Subsidiaries during the vesting period for such Eligible RSUs and the denominator of which is the total number of months in the vesting period for such Eligible RSUs. By way of illustration, if any such Eligible RSUs were scheduled to vest in equal one-third (1/3) installments on each of the first three (3) anniversaries of the date of grant, and the Participant were to experience a Covered Termination after completing eighteen (18) full months of the original thirty-six (36)-month vesting period, then an additional one-half (1/2) of the Eligible RSUs that were unvested as of the Participant's Date of Termination would become vested effective as of the Participant's Date of Termination and the remaining unvested Eligible RSUs would be immediately forfeited.

d. Prorated vesting of any outstanding and unvested award of Eligible PSUs held by a Participant on the Participant's Date of Termination, on the date such Eligible PSUs would have otherwise vested based on actual performance results following completion of the full performance period, with the number of Eligible PSUs vesting determined by multiplying (i) the number of unvested Eligible PSUs that would have vested based on the actual results as certified by the Committee by (ii) a fraction, the numerator of which is the number of full months the Participant was employed by the Company or any of its Subsidiaries during the performance period for such Eligible PSUs and the denominator of which is the total number of months in the performance period for such Eligible PSUs. For the avoidance of doubt, all equity-based compensation other than Eligible RSUs and Eligible PSUs granted by the Company to the Participant under any Equity Plan shall vest or become earned or forfeited pursuant to the terms of such Equity Plan and the Participant's applicable grant agreement.

e. Outplacement services during the Outplacement Period at the expense of the Company. The outplacement services shall be made available through, and at the facilities of, a vendor selected by the Company.

5. NO DUPLICATION OF BENEFITS

1. In the event that the Participant is entitled to receive cash severance benefits under any Termination Arrangement, including pay in lieu of advance notice of termination (the "**Other Cash Severance**"), the amount of any Cash Severance Payment payable under Section 4(a) of this Plan shall be reduced by the amount of Other Cash Severance, but not to less than zero (0). Notwithstanding the foregoing, any cash severance amount payable to a Participant pursuant to an offer letter or similar agreement or contract with the Company that references Make-Whole Awards (the "**Make-Whole Severance**") is expressly excluded from the definition of Other Cash Severance for purposes of this Plan, and on a Covered Termination the Participant may be entitled to both the Cash Severance Payment and Make-Whole Severance, and such Make-Whole Awards shall not be considered Eligible RSUs or Eligible PSUs for purposes of this Plan and shall not be entitled to any acceleration in accordance with Section 4(c) or 4(d) hereof.

2. In the event that the Participant is eligible to receive under any Termination Arrangement on a Covered Termination either (i) continued healthcare coverage, or payment in respect of continued healthcare coverage (the "**Healthcare Benefits**") or (ii) outplacement services, the Participant shall be entitled to receive the more favorable

of the Healthcare Benefits and/or outplacement services under the Termination Arrangement or under Section 4(b) or Section 4(e) of this Plan, as applicable. For the avoidance of doubt, in no event shall the Participant be entitled to Healthcare Benefits or outplacement services under both a Termination Arrangement and this Plan.

3. Notwithstanding anything in this Plan to the contrary, if the treatment of any Eligible RSUs or Eligible PSUs on a Covered Termination is more favorable to the Participant pursuant to the terms of the Participant's grant agreement applicable to such Eligible RSUs or Eligible PSUs (including as a result of the Participant's retirement eligibility) than the provisions in Sections 4(c) or 4(d) of this Plan, the provisions of the applicable grant agreement shall control over any provisions to the contrary in this Plan.

4. If the Participant is eligible to receive any benefit or perquisite on a Covered Termination under any Termination Arrangement that does not constitute Other Cash Severance, Healthcare Benefits, outplacement services or equity award acceleration, the Participant shall remain eligible to receive such benefit or perquisite in addition to the Severance Benefits pursuant to this Plan in accordance with the terms of the applicable Termination Arrangement.

5. For the avoidance of doubt, in the event that the Participant is eligible to receive any severance payments or benefits under any Termination Arrangement on a termination of employment other than a Covered Termination (e.g., a Participant's termination of employment for "good reason"), this Plan shall not apply to such termination of employment and the Participant shall remain eligible to receive such payments or benefits in accordance with the terms of such Termination Arrangement and not eligible for the Severance Benefits.

6. CONDITIONS TO RECEIPT OF SEVERANCE BENEFITS

1. Payment of the Severance Benefits shall be subject to (i) the Participant's execution (and non-revocation) of a general release of claims in favor of Intel and its affiliates in a form reasonably provided by the Company (the "Release") within the time period specified therein, and (ii) the Release becoming effective and irrevocable in accordance with its terms within sixty (60) days following the Participant's Date of Termination. If the Release does not become irrevocably effective within sixty (60) days following the Participant's Date of Termination due to action or inaction of the Participant, the Participant shall forfeit all rights to the Severance Benefits.

2. To the extent requested by the Company, the Participant shall deliver to the Company in writing a notice of resignation from, as applicable, all offices, directorships, and fiduciary positions with the Company, its Subsidiaries, or affiliates and employee benefit plans.

7. TAX WITHHOLDING

Any Severance Benefits payable pursuant to this Plan shall be subject to withholdings for all applicable federal, state, local, and foreign taxes and any other required payroll deductions.

8. PLAN AMENDMENT OR TERMINATION

The Committee reserves the right to amend, modify, suspend, or terminate this Plan at any time; provided that, notwithstanding the foregoing, no such amendment, modification, suspension, or termination that has the effect of reducing or diminishing the rights of any Participant under this Plan, shall be effective without the written consent of the Participant.

9. SECTION 409A

1. The Company intends that the reimbursements, payments, and benefits to which a Participant could become entitled under this Plan be exempt from or comply with Section 409A of the Code ("Section 409A") and the regulations and other guidance promulgated thereunder. The provisions of this Section 9 shall qualify and supersede all other provisions of this Plan as necessary to fulfill the foregoing intention. If the Company believes, at any time, that any of such reimbursement, payment or benefit is not exempt or does not so comply, the Company shall

promptly advise the Participant and shall reasonably and in good faith amend the terms of such arrangement such that it is exempt or complies (with the most limited possible economic effect on the Participant and on the Company) or to minimize any additional tax, interest, and/or penalties that may apply under Section 409A if exemption or compliance is not practicable. The Company agrees that it shall not without a Participant's prior written consent, knowingly take any action, or knowingly refrain from taking any action, other than as required by law, that would result in the imposition of tax, interest, and/or penalties upon the Participant under Section 409A, unless such action or omission is pursuant to the Participant's written request.

2. To the extent applicable, each and every payment to be made pursuant to Section 4 of this Plan shall be treated as a separate payment and not as one of a series of payments treated as a single payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).

3. If a Participant is a 'specified employee' (determined by the Company in accordance with Section 409A and Treasury Regulation Section 1.409A-3(i)(2)) as of the date that the Participant experiences a 'separation from service' with the Company, as defined for purposes of Section 409A (a "Separation from Service"), and if any reimbursement, payment, or benefit to be paid or provided under this Plan or otherwise both (i) constitutes a 'deferral of compensation' within the meaning of and subject to Section 409A ("Nonqualified Deferred Compensation") and (ii) cannot be paid or provided in a manner otherwise provided herein without subjecting the Participant to additional tax, interest, and/or penalties under Section 409A, then any such reimbursement, payment, or benefit that is payable during the first six (6) months following the Participant's Date of Termination shall be paid or provided to the Participant in a lump sum cash payment to be made on the earlier of (A) the Participant's death and (B) the first business day of the seventh (7th) month immediately following the Participant's Separation from Service or as soon as administratively practicable after such date.

4. Except to the extent any reimbursement, payment, or benefit to be paid or provided under this Plan does not constitute Nonqualified Deferred Compensation, (i) the amount of expenses eligible for reimbursement or the provision of any in-kind benefit (as defined in Section 409A) to a Participant during any calendar year shall not affect the amount of expenses eligible for reimbursement or provided as in-kind benefits to the Participant in any other calendar year (subject to any lifetime and other annual limits provided under the Company's health plans), (ii) the reimbursements for expenses for which a Participant is entitled shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred, and (iii) the right to payment or reimbursement or in-kind benefits may not be liquidated or exchanged for any other benefit.

5. Any reimbursement, payment, or benefit to be paid or provided under Section 4 hereof or otherwise to be paid or provided due to a Separation from Service that is exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9)(v) shall be paid or provided to a Participant only to the extent the expenses are not incurred or the benefits are not provided beyond the last day of the Participant's second taxable year following the Participant's taxable year in which the Separation from Service occurs; provided, however, that the Company shall reimburse such expenses no later than the last day of the third taxable year following the Participant's taxable year in which the Participant's Separation from Service occurs.

6. Subject to Section 4, any reimbursement, payment, or benefit to be paid or provided under this Plan that constitutes Nonqualified Deferred Compensation due upon a termination of employment shall be paid or provided to a Participant only in the event of a Separation from Service.

10. GOVERNING LAW

This Plan is intended to be an unfunded 'top-hat' welfare plan, within the meaning of U.S. Department of Labor Regulation Section 2520.104-24 and shall be interpreted, administered, and enforced in accordance with ERISA. It is expressly intended that ERISA preempt the application of state laws to this Plan, to the maximum extent permitted by Section 514 of ERISA. To the extent that state law is applicable, the statutes and common laws of the State of Delaware shall apply.

11. BENEFIT CLAIMS AND APPEALS

1. **Benefit Claims.** If any person (claimant) believes that Severance Benefits are being denied improperly, that this Plan is not being operated properly, or that the claimant's legal rights are being violated with respect to this Plan, the claimant must file a claim with the Committee no later than the earlier of (i) sixty (60) days after the claimant's termination of employment or (ii) ninety (90) days after the date the claimant first knew or should have known of the facts on which the claim is based. If such claim for benefits is wholly or partially denied, the Committee shall within a reasonable period of time, but no later than ninety (90) days after receipt of the written claim, notify the claimant of the denial of the claim. If an extension of time for processing the claim is required, the Committee may take up to an additional ninety (90) days, provided that the Committee sends the claimant written notice of the extension before the expiration of the original ninety (90)-day period. The notice provided to the claimant shall describe why an extension is required and when a decision is expected to be made. If a claim is wholly or partially denied, the denial notice will: (i) be in writing, (ii) be written in a manner calculated to be understood by the claimant, and (iii) contain (A) the reasons for the denial, including specific reference to those Plan provisions on which the denial is based; (B) a description of any additional information necessary to complete the claim and an explanation of why such information is necessary; (C) an explanation of the steps to be taken to appeal the adverse determination; and (D) a statement of the claimant's right to bring a civil action under Section 502(a) of ERISA following an adverse decision after appeal. The Committee shall have full discretion consistent with their fiduciary obligations under ERISA to deny or grant a claim in whole or in part. If notice of denial of a claim is not furnished in accordance with this Section, the claim shall be deemed denied and the claimant shall be permitted to exercise his or her rights to review described below.

2. **Appeals.** Within sixty (60) days of the claimant's receipt of the written notice of denial of the claim, the claimant may file a written request for a review of the denial of the claimant's claim for benefits. In connection with the claimant's appeal of the denial of his or her benefit, the claimant may submit comments, records, documents, or other information supporting the appeal, regardless of whether such information was considered in the prior benefits decision. Upon request and free of charge, the claimant shall be provided reasonable access to and copies of all documents, records, and other information relevant to the claim. The Committee shall deliver to the claimant a written decision on the claim promptly, but not later than sixty (60) days after the receipt of the claimant's written request for review, except that if there are special circumstances which require an extension of time for processing, the sixty (60)-day period shall be extended to one hundred twenty (120) days; provided that the appeal reviewer sends written notice of the extension before the expiration of the original sixty (60) -day period. If the appeal is wholly or partially denied, the denial notice will: (i) be in writing, (ii) be written in a manner calculated to be understood by the claimant, and (iii) contain (A) the reasons for the denial, including specific reference to those Plan provisions on which the denial is based; (B) a statement that, upon request and free of charge, the claimant shall be provided reasonable access to and copies of all documents, records and other information relevant to the claim for benefits; and (C) a statement of the claimant's right to bring a civil action under Section 502(a) of ERISA. No legal action shall be brought against this Plan, the Committee, or the Company after sixty (60) days from receipt of the final decision on a claim appeal.

3. The procedure set forth in this Section 11 is intended to comply with United States Department of Labor Regulation Section 2560.503-1 and should be construed in accordance with such regulation. In no event shall the claims procedure be interpreted as expanding the rights of a Participant beyond what is required by United States Department of Labor Regulation Section 2560.503-1.

12. NOTICES

Notices and all other communications provided for under this Plan shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by United States certified mail, return receipt requested, or by overnight courier, postage prepaid, to the Company's corporate headquarters address, to the attention of the Committee, or to the Participant at the last address shown on the payroll records of the Company.

13. MISCELLANEOUS

1. **Successors.** Any successor to Intel of all or substantially all of Intel's business and/or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) shall assume the obligations

under this Plan and agree expressly to perform the obligations under this Plan in the same manner and to the same extent as Intel would be required to perform such obligations in the absence of a succession. For all purposes under this Plan, the term "Company" shall include any successor to the Company's business and/or assets which become bound by the terms of this Plan by operation of law, or otherwise.

2. Indemnification. To the extent permitted by law and Intel's Bylaws, the Company shall indemnify the Committee from all claims for liability, loss, or damage (including the advancement of expenses in connection with defense against such claims) arising from any act or failure to act in connection with this Plan.

3. Severability. If any provision of this Plan is held invalid or unenforceable, its invalidity or unenforceability shall not affect any other provision of this Plan, and this Plan shall be construed and enforced as if such provision had not been included.

4. Employment Status. Neither this Plan, the selection of a person as a Participant, nor any action by the Company or the Committee shall be held or construed to confer upon any person any right to be continued in the employ of the Company. The Company expressly reserves the right to terminate the employment of any Participant whenever in the sole discretion of the Company its interest may so require.

5. Compensation Recoupment Policy. Notwithstanding any provision in this Plan to the contrary, amounts paid or payable under this Plan shall be subject to the terms and conditions of the Intel Corporation Compensation Recoupment Policy, as may be amended from time to time (the "Compensation Recoupment Policy"), to the extent applicable (including by reason of such amounts being calculated or determined by reference to an underlying amount or payment that is subject to the Compensation Recoupment Policy).

6. Relation to other Arrangements. This Plan is intended to be consistent with the Intel Corporation Executive Officer Cash Severance Policy, as may be amended from time to time (the "Severance Policy"). The Committee may take such actions as it deems necessary to implement and administer this Plan consistent with the terms of the Severance Policy.

7. Unfunded Plan. This Plan shall be unfunded, and all benefits hereunder shall be paid only from the general assets of the Company.

EXHIBIT A

Tier	Severance Multiplier	Severance Period	Outplacement Period
Grades 16-17	1.5x	18 months	18 months
Grades 14-15	1.0x	12 months	6 months

EXHIBIT B

Excluded Subsidiaries

- Mobileye Global Inc.
- Habana Labs Ltd.
- Moovit App Global Ltd.
- IMS Nanofabrication
- Altera Corporation

CERTIFICATION

I, Patrick P. Gelsinger, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Intel Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2024

By: /s/ PATRICK P. GELSINGER

Patrick P. Gelsinger
Chief Executive Officer, Director and Principal Executive Officer

CERTIFICATION

I, David Zinsner, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Intel Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2024

By: /s/ DAVID ZINSNER

David Zinsner
Executive Vice President, Chief Financial Officer and
Principal Financial Officer

CERTIFICATION

Each of the undersigned hereby certifies, for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Intel Corporation (Intel), that, to his knowledge, the Quarterly Report of Intel on Form 10-Q for the period ended June 29, 2024, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Intel. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to such Form 10-Q. A signed original of this statement, which may be electronic, has been provided to Intel and will be retained by Intel and furnished to the Securities and Exchange Commission or its staff upon request.

Date: August 1, 2024

By: /s/ PATRICK P. GELSINGER

Patrick P. Gelsinger

Chief Executive Officer, Director and Principal Executive Officer

Date: August 1, 2024

By: /s/ DAVID ZINSNER

David Zinsner

Executive Vice President, Chief Financial Officer, and
Principal Financial Officer